documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig report also refers trademarks service marks trade names companiesthis annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs plans expectations respect products product candidates corporate strategy business operations financial projections use capital collaboration licensing arrangements ongoing litigation investigation matters statements regarding anticipated future impact business ongoing coronavirus disease covid related public health measures statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item annual report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof unless otherwise specified except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise evaluating business carefully consider risks described section entitled risk factors part item annual report risks contained herein could materially adversely affect business results operations financial condition part item business gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california business products innovative medicines represent advancements offering firstinclass treatments greater efficacy enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects focus innovation allowed us deliver marketed products across multiple therapeutic areas primary revenuegenerating products approved indications united states follows hivaids biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy singletablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine tenofovir alafenamide taf genvoya oral formulation dosed day treatment hiv infection certain patients genvoya singletablet regimen fixeddose combination antiretroviral medicines elvitegravir cobicistat emtricitabine taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications emtricitabine taf descovy also approved us food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquired hiv infection certain atrisk patients odefsey oral formulation dosed day treatment hiv infection certain patients odefsey singletablet regimen fixeddose combination antiretroviral medications emtricitabine taf rilpivirine marketed janssen sciences ireland unlimited company one janssen pharmaceutical companies johnson johnson janssen truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients truvada fixeddose combination antiretroviral medications tenofovir disoproxil fumarate tdf emtricitabine truvada also approved fda prep indication reduce risk sexually acquired hiv infection certain atrisk patients compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed united states complera europe eviplera singletablet regimen fixeddose combination antiretroviral medications tdf emtricitabine janssens rilpivirine hydrochloride stribild oral formulation dosed day treatment hiv infection certain patients stribild singletablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tdf emtricitabine atripla oral formulation indicated complete regimen treatment hiv infection certain patients atripla fixeddose combination antiretroviral medications tdf emtricitabine bristolmyers squibb company bmss efavirenz covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicated treatment coronavirus disease covid certain adults children years age older weighing least pounds kg hospitalized ii hospitalized mildtomoderate covid high risk progression severe covid including hospitalization death indication received expedited approval fda january liver diseases epclusa oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adults certain pediatric patients genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin addition authorized generic version epclusa distributed separate subsidiary asegua therapeutics llc harvoni oral formulation oncedaily singletablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii adults genotype decompensated cirrhosis combination ribavirin iii adults genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin iv certain pediatric patients genotype without cirrhosis compensated cirrhosis addition authorized generic version harvoni distributed separate subsidiary asegua therapeutics llc vosevi oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adults genotype previously treated nsa inhibitorcontaining regimen ii genotype previously treated sofosbuvircontaining regimen without nsa inhibitor vemlidy oral formulation taf dosed day treatment chronic hepatitis b virus hbv infection adults compensated liver disease viread oral formulation tdf dosed day treatment chronic hbv infection adults certain pediatric patients hematologyoncologycell therapy yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car tcell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy including diffuse large bcell lymphoma dlbcl otherwise specified primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arising follicular lymphoma ii adult patients relapsed refractory follicular lymphoma fl two lines systemic therapy indication approved accelerated approval fda continued approval indication may contingent upon verification description clinical benefit confirmatory trials tecartus brexucabtagene autoleucel suspension intravenous infusion car cell therapy treatment adult patients relapsed refractory mantle cell lymphoma mcl ii adult patients relapsed refractory bcell precursor acute lymphoblastic leukemia trodelvy sacituzumab govitecanhziy injection intravenous use trop directed antibody topoisomerase inhibitor conjugate indicated treatment adult patients unresectable locally advanced metastatic triplenegative breast cancer tnbc received two prior systemic therapies least one metastatic disease ii adult patients locally advanced metastatic urothelial cancer previously received platinumcontaining chemotherapy either programmed death receptor pd programmed deathligand pdl inhibitor indication approved accelerated approval fda continued approval indication may contingent upon verification description clinical benefit confirmatory trials zydelig idelalisib oral formulation kinase inhibitor treatment patients relapsed chronic lymphocytic leukemia combination rituximab rituximab alone would considered appropriate therapy due comorbidities letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults information revenuegenerating products including amount revenue contributed products listed see note revenues notes consolidated financial statements included part ii item annual report revenue share revenues also generate revenues activities including revenue share combination products royalties outbound licenses intellectual property payments received collaborations thirdparty partners example pursuant collaboration janssen receive revenue share cobicistat emtricitabine taf components symtuza darunavircobicistatemtricitabinetaf fixeddose combination product commercialized janssen include revenue share symtuza product sales description collaborations janssen partners see note collaborations arrangements notes consolidated financial statements included part ii item annual report form k commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products united states exclusively wholesale channel year ended december approximately product sales united states approximately total worldwide revenues three large wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute products europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected research development research development rd mission discover develop transformational therapies areas high unmet medical need product development efforts focused primarily viral diseases inflammatory diseases oncology team research scientists engaged discovery development new molecules technologies hope lead approval innovative medicines therapies advance current standard care address unmet medical needs intend continue committing significant resources internal rd opportunities external business development activity drive innovation growth business development product candidates investigational therapies pipeline subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials including account clinical holds placed regulatory authorities perform additional trials risk failing obtain regulatory approvals result product candidates investigational therapies may never successfully commercialized drug development inherently risky many product candidates investigational therapies fail development process continued invest advance rd pipeline across therapeutic areas summary product candidates phase registrational phase clinical trials pending marketing authorization review fda european medicines agency ema end product candidates viral diseases product candidates description regulatory filings lenacapavir new drug application marketing authorization application filed fda ema respectively lenacapavir hiv capsid inhibitor component longacting regimen treatment hiv infection heavily treatmentexperienced people living hiv granted breakthrough therapy designation fda indication bulevirtide biologics license application filed fda bulevirtide treatment chronic hepatitis delta virus hdv infection granted orphan drug breakthrough therapy designations fda indication europe hepcludex bulevirtide granted conditional marketing authorization european commission priority medicines prime scheme eligibility ema first approved treatment adults chronic hdv infection compensated liver disease phase lenacapavir lenacapavir evaluated hiv prep indication program timeline pending resolution clinical hold placed fda studies evaluating injectable lenacapavir product candidates inflammatory diseases product candidate description phase cilofexor cilofexor fxr agonist evaluated treatment primary sclerosing cholangitis filgotinib filgotinib jak inhibitor evaluated treatment crohns disease product candidates oncology product candidates description regulatory filings yescarta axicabtagene ciloleucel supplemental biologics license application type ii variation marketing authorization application filed fda ema respectively axicabtagene ciloleucel car cell therapy treatment secondline dlbcl type ii variation marketing authorization application filed ema axicabtagene ciloleucel treatment relapsed refractory fl yescarta received accelerated approval fda treatment adult patients relapsed refractory fl two lines systemic therapy tecartus brexucabtagene autoleucel type ii variation marketing authorization application filed ema brexucabtagene autoleucel car cell therapy treatment adult tecartus received fda approval treatment adult patients relapsed refractory bcell precursor phase sacituzumab govitecanhziy sacituzumab govitecanhziy trop directed antibody topoisomerase inhibitor conjugate evaluated hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer ii nonsmall cell lung cancer nsclc secondline thirdline treatment magrolimab magrolimab anticd evaluated higher risk myelodysplastic syndrome mds firstline treatment ii acute myeloid leukemia aml firstline treatment program timelines pending resolution partial clinical holds placed fda studies evaluating magrolimab zimberelimab zimberelimab antipd monoclonal antibody evaluated nsclc firstline treatment domvanalimab domvanalimab fcsilent antitigit antibody evaluated nsclc firstline treatment registrational phase brexucabtagene autoleucel brexucabtagene autoleucel evaluated treatment pediatric collaboration arcus biosciences inc arcus see note collaborations arrangements notes consolidated financial statements included part ii item annual report additional information regarding collaboration also received regulatory approvals authorizations fda european commission expand indications products including product regulatory approval authorization biktarvy fda approved new lowdose tablet dosage form biktarvy pediatric patients weighing least kg less kg virologically suppressed new antiretroviral therapy epclusa fda approved expansion pediatric indication epclusa treatment chronic hcv infection include pediatric patients years age older regardless hcv genotype liver disease severity veklury european commission approved variation conditional marketing authorization veklury include adults require supplemental oxygen increased risk progressing severe covid yescarta fda granted accelerated approval yescarta treatment adult patients relapsed refractory fl tecartus fda approved tecartus treatment adult patients relapsed refractory bcell precursor trodelvy fda granted full approval trodelvy adult patients unresectable locally advanced metastatic tnbc fda granted accelerated approval trodelvy use adult patients locally advanced metastatic uc european commission granted marketing authorization trodelvy monotherapy indicated treatment adult patients unresectable metastatic tnbc received two prior systemic therapies least one advanced disease addition seek enhance commercial portfolio clinical pipeline across multiple therapeutic areas acquisitions inlicensing strategic collaborations example october entered clinical trial collaboration merck sharp dohme corp subsidiary merck co inc merck evaluate trodelvy combination mercks keytruda patients firstline metastatic tnbc november expanded research collaboration arcus exercised options three programs arcuss clinicalstage portfolio including domvanalimab phase studies nsclc strategic business development activity reflects commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents key product candidates described product candidates fixeddose combinations singletablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients singletablet regimen key product candidates patent expiration us eu viral diseases lenacapavir bulevirtide inflammatory diseases cilofexor filgotinib oncology axicabtagene ciloleucel brexucabtagene autoleucel sacituzumab govitecanhziy magrolimab zimberelimab domvanalimab composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite gilead company kite application patent term extension filed united states granted would extend us expiration date least regulatory exclusivity united states expires collaboration arcus following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents principal products products fixeddose combinations singletablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients singletablet regimen products patent expiration us eu ranexa descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy jyseleca hepcludex estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted gilead lupin limited reached agreement settle patent litigation matter related ranexa applications patent term extensions pending united states andor spcs pending one countries european union products composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite gilead mylan pharmaceuticals reached agreement settle patent litigation concerning patents protect cobicistat stribild genvoya products application patent term extension filed united states granted would extend us expiration date least regulatory exclusivity united states expires patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api hiv products well cell therapy products held third parties acquired exclusive rights patents agreements parties may obtain patents certain products many years marketing approval obtained patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputation may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use sofosbuvir axicabtagene ciloleucel brexucabtagene autoleucel tenofovir disoproxil tenofovir alafenamide bictegravir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries description significant pending legal proceedings see note commitments contingencies notes consolidated financial statements included part ii item annual report see also item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partners cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites cell therapy products established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities manufacture distribute certain products api clinical andor commercial uses facilities include foster city california conduct process chemistry research formulation development activities manufacture api drug product clinical trials oversee thirdparty contract manufacturers san dimas la verne california manufacture ambisome also package label majority commercial products distribution americas pacific rim oceanside california utilize facility clinical manufacturing process development biologics candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy products frederick maryland utilize facility clinical manufacturing processing cell therapy products morris plains new jersey utilize facility manufacturing monoclonal antibody intermediate process optimization antibody drug conjugate products cork dublin ireland utilize cork facility commercial manufacturing packaging labeling products also perform quality control testing labeling packaging final release many products cork facility distributed european union international markets facility dublin utilize facility central dublin drug development hub pediatric programs perform clinical development safety quality biostatistics data sciences regulatory compliance functions edmonton canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes hoofddorp netherlands utilize facility commercial manufacturing processing cell therapy products thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions information thirdparty manufacturers see item risk factors may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities observe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies cell therapy products required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues human capital gileads success depends work dedicated employees embrace shared sense purpose culture excellence human capital objective make gilead employer choice best talent industry gileads key priorities human capital management include inclusion diversity health safety total rewards employee development engagement compensation talent committee board directors oversees overall human capital management inclusion diversity inclusion gilead core value believe building inclusive diverse workforce critical enabling gileads mission global inclusion diversity council responsible governance matters tracking progress goals promoting culture inclusion global inclusion diversity council chaired chairman chief executive officer includes members leadership team introduced advancing black leadership strategy multiyear initiative outlines commitments create internal external pipelines diverse talent build awareness capabilities accountability among people managers part strategy set clear targets representation within overall workforce executive populations including goals increase percentage female black hispanic employees welldefined annual targets gilead also implemented multiple programs train managers inclusion diversity topics created strategies initiatives focused attracting developing retaining diverse talent driving inclusive culture workplace organizational leaders required regularly review starting addition employee resource groups ergs support diverse employees aim raise awareness different cultures within workplace cultivate diversity business strength support gileads talent acquisition strategy source attract recruit diverse candidates executive sponsors leaders ergs contribute advancement inclusion diversity commitments service global inclusion diversity council believe gileads inclusive diverse workforce foundation innovation productivity gileads commitment equal employment opportunity furthers efforts cultivate celebrate equitable culture belonging december gilead approximately employees gileads global workforce approximately female male additionally women represented gileads leadership defined vice president level united states based employees voluntary selfidentification workforce white asian hispanic black health safety gilead committed providing workplace employees promotes health safety wellness productivity workplace safety training security program together various compliance protocols support commitment routinely train educate employees workplace safety security response covid pandemic gilead sites required flexible location employees work home employees needed physically present positions laboratory technicians continued work gilead sites fourth quarter gilead transitioned return tosite phase us flexible location employees pandemic implemented job site enhancements risk protocols including health screenings covid testing vaccine requirements reconfiguration work common spaces allow physical distancing effort support safe occupancy sites gilead also maintains robust contact tracing notification process employee reports covid infection continue monitor state pandemic remain committed maintaining work environment promotes health safety productivity workforce total rewards gileads compensation benefits programs designed help attract develop retain industrys talented workforce total rewards program varies country includes competitive base salary incentive compensation stock awards employee stock purchase plan k savings plan company match vests immediately health welfare valuable benefits flexible work arrangements flexible spending accounts paid time family leave family care resources fertility adoption surrogacy assistance student loan repayment tuition assistance employee assistance programs global wellbeing reimbursement tuition assistance among many others year reassess total rewards package confirm whether offers benefits incentives align total reward philosophy payforperformance company committed addressing pay equity employee salaries informed marketbased ranges assessed annually performance career development reviews policy compensation decisions made without regard personal characteristics gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status also conduct annual pay equity review employee compensation effort strive make pay practices gender race neutral employee development engagement employee development engagement maximizes potential performance member workforce critical achieving business goals gilead offers number internal external professional management leadership development training programs help employees develop technical crossfunctional leadership skills tools grow careers addition employees receive reimbursement tuition expenses incurred pursuing undergraduate graduate certificate courses accredited college university strive employer choice industry listening strategy gathers input employees shape engagement strategies programs measure progress addition ongoing internal external data collection conducted largescale review employee experience employee survey results survey played key role determining direction culture well companys broader response continuing covid pandemic including meaningful benefits provided employees approach flexible work arrangements believe flexible work program positions us competitive talent support employee wellbeing also creating collaborative environment connections fuel innovation environmental social governance esg investing corporate responsibility core business strategy reflects values accountability inclusion teamwork excellence integrity service mission advance global health providing innovative therapeutics areas unmet need way socially responsible environmentally sustainable gileads esg programs reflect commitment stakeholders esg strategy performance overseen nominating corporate governance committee board directors managed corporate responsibility committee comprised leaders key departments across company corporate responsibility committee responsible reviewing material esg issues integrating overall business strategy operations additional information program esg highlights available gileads year review gileads website wwwgileadcomnewsandpressannualreportyearinreview esg goals aspirational may change statements regarding goals related initiatives guarantees promises met seasonality operations worldwide product sales reflect significant degree seasonality enduser demand however united states fluctuations wholesaler inventory levels impact product sales typically observe strong wholesaler subwholesaler purchases products fourth quarter resulting inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds covid pandemic buying patterns also could impact product sales recorded particular quarter information see item risk factors face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories government regulation operations activities subject extensive regulation numerous government authorities united states european union countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming significant impact capital expenditures results operations regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda united states ema european commission european union well national authorities european union member states must approve drug sold respective country countries general process drug approval united states summarized many countries including countries european union european union centralized procedure similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering risk indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating preventing disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective appropriate safety profile phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application biologics license application supplemental application fda seeking approval sell drug candidate particular use fdas discretion fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees drug met required level safety efficacy particular use approve application allow us sell drug united states use unusual however fda decline approve application believes drug candidate safe enough efficacious enough ie appropriate benefitrisk profile believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit manufacturing issues certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit even approving drug fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards concerns safety efficacy uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland netherlands also must obtain local licenses permits compliance local regulatory requirements fda may employ one several tools facilitate expedite development review drug including fast track designation breakthrough therapy designation accelerated approval priority review designation fast track designation designed facilitate development review drug treats serious condition fills unmet medical need breakthrough therapy designation designed expedite development review drug treats serious condition preliminary clinical evidence demonstrates substantial improvement available therapies accelerated approval drug may granted fda drug treats serious condition fills unmet medical need studied safety efficacy priority review designation means fdas goal take action application within six months filing fda may grant priority review designation drug would provide significant improvement safety effectiveness treatment diagnosis prevention serious condition european union regulatory system approval process european union eu products subject variety eu eu member state regulations governing clinical trials commercial sales distribution required obtain marketing authorization eu market medicinal products relevant market conduct clinical trials eu governed among others directive ec directive ec eu ich good clinical practice rules impose legal regulatory obligations similar provided applicable us laws conduct clinical trials eu must approved competent authorities eu member states clinical trials take place positive opinion must obtained relevant ethics committee relevant member state eu legislator adopted regulation eu replace directive ec introduce coordinated procedure authorization clinical trials regulation entered application january marketing authorization holders manufacturers importers wholesalers distributors medicinal products placed market eu required comply number regulatory requirements including pharmacovigilance gmp compliance requirement obtain manufacturing import andor distribution licenses issued competent authorities eu member states failure comply requirements may lead imposition civil criminal administrative sanctions including suspension marketing manufacturing authorizations pricing reimbursement successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices including rebates may required pay medicaid agencies discounts may required pay b covered entities result price increases implement time time certain products may limited effect net product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories health care fraud abuse laws antibribery laws subject various us federal state laws pertaining health care fraud abuse including antikickback laws false claim laws anti kickback laws make illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimbursed federal healthcare program including purchase prescription particular drug false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim addition fda regulates written verbal communications products addition federal law states also consumer protection false claims laws due breadth statutory provisions attention given law enforcement authorities sales marketing patient support medical clinical public affairs activities may subject scrutiny laws example recently enhanced scrutiny government enforcement authorities companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance reimbursement support offerings clinical education programs promotional speaker programs similarly europe interactions pharmaceutical companies physicians subject strict laws regulations industry selfregulation codes conduct physicians codes professional conduct applicable including eu member states anticorruption laws uk bribery act addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us unlawful acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program even disagree governments perspective violated rules guidance similar violations competitors could also negatively impact reputation industry increase governmental public scrutiny business products us healthcare reform us federal state governments continue propose pass legislation designed regulate healthcare industry including legislation seeks indirectly directly regulate pharmaceutical drug pricing information see item risk factors impacted evolving laws regulations legislative regulatory actions applicable health care industry environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements securities exchange act exchange act therefore file periodic reports proxy information statements information sec sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec website wwwgileadcom link investors website sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act website references provided throughout document convenience content referenced websites constitute part incorporated reference annual report item risk factors evaluating business carefully consider following discussion material risks events uncertainties make investment us speculative risky addition information annual report manifestation following risks uncertainties could circumstances may may able accurately predict materially adversely affect business operations growth reputation including commercial scientific reputation products prospects product pipeline sales operating financial results financial condition cash flows liquidity stock price note factors investors permitted private securities litigation reform act possible predict identify factors operations could also affected factors events uncertainties presently known us currently consider present significant risks operations therefore consider following risks complete statement potential risks uncertainties face product commercialization risks certain products subject us additional heightened risks hiv products receive substantial portion revenue sales products treatment prevention hiv infection sales hiv products accounted approximately total product sales may unable sustain increase sales hiv products number reasons including market share gains competitive products including generics inability introduce new hiv medications necessary remain competitive case may need scale back operations including future drug development spending research development rd efforts example many hiv products contain tenofovir alafenamide taf belongs nucleoside class antiviral therapeutics changes treatment paradigm hiv may cause nucleosidebased therapeutics fall favor veklury face risks related supply distribution veklury approved us food drug administration fda october treatment patients hospitalized coronavirus disease covid january treatment nonhospitalized adult adolescent patients high risk progression severe covid including hospitalization death utilization veklury largely tracked rates covid hospitalizations unable accurately predict revenues supply needs short long term due dynamic nature pandemic including availability uptake effectiveness vaccines alternative treatments covid fluctuating hospital utilization rates emergence new variants timing surges infection accurately forecast demand manufacture veklury levels sufficient meet demand may experience product shortages build excess inventory may written also remain subject significant public attention scrutiny complex decisions made regarding clinical data supply allocation distribution pricing veklury affects corporate reputation cell therapy advancing novel personalized therapy yescarta tecartus chimeric antigen receptor car cell therapies creates significant challenges including educating certifying medical personnel regarding procedures potential side effects cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy program required fda securing sufficient supply medications manage side effects tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impacts efficacy cell therapy developing maintaining robust reliable process engineering patients cells facilities infusing back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community fda approved cell therapies including yescarta tecartus must continue demonstrate medical community potential advantages cell therapy compared existing future therapeutics challenges related reimbursement yescarta tecartus see also existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures rely thirdparty sites collect patients white blood cells known apheresis centers well shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta tecartus patients vendors may encounter disruptions difficulties could result product loss regulatory action apheresis centers may also choose participate quality certification process may unable complete certification timely manner could delay constrain manufacturing commercialization efforts operate new automated manufacturing facility frederick maryland facility pending fda approval commercial manufacturing even obtain approval manufactured products automated facility commercial scale result may able produce otherwise obtain amount supply sufficient satisfy demand products unable meet product demand difficulty meeting sales forecasts products plan manufacture facility success depends developing commercializing new products expanding indications existing products unable launch commercially successful new products new indications existing products business adversely impacted launch commercially successful products necessary grow business cover substantial rd expenses offset revenue losses existing products lose market share due factors competition loss patent exclusivity many difficulties uncertainties inherent drug development introduction new products product development cycle characterized significant investments resources long lead times unpredictable outcomes due nature developing medicines human use expend significant time resources product pipeline without assurance recoup investments efforts commercially successful high rate failure inherent discovery development new products failure occur point process including late process substantial investment face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories may unable accurately predict demand products including uptake new products demand depends number factors example product demand may adversely affected physicians see benefit products additionally nonretail sector united states includes government institutions including state aids drug assistance programs us department veterans affairs correctional facilities large health maintenance organizations tends less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products expect continue experience fluctuations purchasing patterns nonretail customers light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels may continue see trend future sell distribute products united states exclusively wholesale channel year ended december approximately product sales united states three wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation us wholesalers entered inventory management agreements make estimates determine enduser demand may completely effective matching inventory levels actual enduser demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match enduser demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even enduser demand changed addition observed strong wholesaler subwholesaler purchases products fourth quarter typically results inventory drawdown wholesalers subwholesalers subsequent first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers new branded generic products entering major markets affects ability maintain pricing market share products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing number companies pursuing development technologies competitive existing products research programs competing companies include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs may adversely impacted competitors gain market share result new technologies commercialization strategies otherwise existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures product reimbursements successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement products mature pricing pressures private insurers government payers often result reduction net product prices legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently example september fda issued final rule implementing pathway importation certain prescription drugs canada rule subject ongoing litigation may adversely impacted legislative regulatory actions though difficult predict impact use reimbursement products product pricing discounts rebates united states european union eu significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services united states volume drug pricingrelated bills dramatically increased recent years example congress enacted laws requiring manufacturer refunds certain amounts discarded drug singleuse vials beginning eliminating existing cap medicaid rebate amounts beginning congress also proposed bills require department health human services negotiate prices certain drugs impose inflationbased rebate medicare part b drugs list prices drugs grow faster inflation increase manufacturer contributions medicare part benefit phases addition many state legislatures considering already passed law legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring manufacturers publicly report proprietary pricing information creating review boards prices state agencies encouraging use generic drugs initiatives legislation may cause added pricing pressures products resulting impact business uncertain many countries outside united states including eu member states established complex lengthy procedures obtain price approvals coverage reimbursement periodically review pricing reimbursement decisions outcome review predicted could adverse effect pricing reimbursement medicinal products eu member states reductions pricing medicinal products one member state could affect price member states negative impact financial results substantial portion product sales subject significant discounts list price including rebates may required pay state medicaid agencies discounts provided b covered entities changes b program medicaid program federal state level could material adverse effect business example december centers medicare medicaid services cms issued final rule make certain changes calculation rebates medicaid drug rebate program among changes effective january final rule change requirements excluding manufacturer copay coupons medicaid best price changes subject ongoing litigation changes go effect could substantially increase medicaid rebate obligations decrease prices charge b covered entities continued growth b program also limits prices may charge increasing percentage sales addition standard reimbursement structures may adequately reimburse innovative therapies example beginning fiscal year cms established new severityadjusted diagnosisrelated group drg medicare inpatient reimbursement car products yescarta tecartus new drg significantly higher base payment amount prior drg payment available may sufficient reimburse hospitals cost care patients receiving yescarta tecartus reimbursement aligned well account treatment costs medicare beneficiaries may denied access misalignment could impact willingness hospitals offer therapy doctors recommend therapy additionally eu barriers reimbursement individual countries could limit uptake yescarta tecartus addition estimate rebates required pay connection sales particular quarter based claims data prior quarters united states actual rebate claims typically made payers one three quarters arrears actual claims payments may vary significantly estimates may experience adverse impacts resulting importation products lower price markets distribution illegally diverted counterfeit versions products prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported resold countries lower price markets example us sales could also affected fda permits importation drugs canada entered agreements generic drug manufacturers well licensing agreements medicines patent pool united nationsbacked public health organization allows generic drug manufacturers manufacture generic versions certain products distribution certain low middleincome countries may adversely affected generic versions products whether produced andor distributed agreements exported united states europe markets higher prices eu required permit products purchased one eu member state sold another member state purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter additionally diverted products may used countries approved patients may source diverted products outside legitimate supply chain diverted products may handled shipped stored inappropriately may affect efficacy products could harm patients adversely impact us also aware existence various suppliers around world source products generic versions products without gileads authorization sell use countries products approved result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances could adversely impact us third parties illegally distributed sold may continue illegally distribute sell illegally diverted counterfeit versions medicines meet rigorous quality standards manufacturing supply chain example part ongoing investigation coordination us marshals local law enforcement recently executed courtordered seizures locations across eight us states seized thousands bottles gileadlabeled medication counterfeit supply chain documentation including bottles labeled biktarvy descovy investigation revealed pharmaceutical distributors authorized gilead sell gilead medicine sold independent pharmacies nationwide purported genuine gilead medicine sourced illegal counterfeiting scheme illegally diverted counterfeit medicines pose serious risk patient health safety actions stop prevent distribution sale illegally diverted counterfeit versions medicines around world may costly unsuccessful may adversely affect reputation business including product revenues financial results product development supply chain risks face risks clinical trials including potential unfavorable results delays anticipated timelines disruption required demonstrate safety efficacy product candidates develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products face numerous risks uncertainties clinical trials could result delays prevent completion development approval product candidates risks uncertainties include challenges clinical trial protocol design ability enroll patients clinical trials possibility unfavorable inadequate trial results support development product candidates including failure meet trials primary endpoint safety issues arising clinical trials need modify delay clinical trials perform additional trials example recently announced clinical holds placed fda clinical trials evaluating injectable lenacapavir lenacapavir combination islatravir magrolimab including combination azacitidine result may unable successfully complete clinical trials anticipated timelines based trial results possible fda regulatory authorities may approve product candidates market approvals may include significant limitations products use addition clinical trials involving commercial products could raise new safety issues existing products could adversely impact business may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline therefore product candidates may never successfully commercialized may unable recoup significant rd clinical trial expenses incurred anticipate continued expansion clinical pipeline includes multiple planned phase study initiations oncology virology expect expend significant time resources clinical trial activities without assurance recoup investments efforts commercially successful also risks associated use third parties clinical trial activities extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals may adversely affected may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners products manufactured facilities thirdparty manufacturers corporate partners result complex highly regulated manufacturing processes depend thirdparty manufacturers corporate partners perform manufacturing activities effectively timely basis majority active pharmaceutical ingredients drug products third parties independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema well comparable regulations jurisdictions manufacturing operations also subject routine inspections regulatory agencies adverse developments affecting resulting manufacturing operations operations thirdparty manufacturers corporate partners may result shipment delays inventory shortages lot failures product withdrawals recalls interruptions commercial supply products may also need take inventory writeoffs incur charges expenses products fail meet specifications quality standards undertake costly remediation efforts seek costly manufacturing alternatives developments could increase manufacturing costs cause us lose revenues market share damage reputation addition manufacturing issues may cause delays clinical trials applications regulatory approval example unable remedy deficiencies cited fda regulatory agencies inspections existing products timing regulatory approval product candidates development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries business may adversely affected approval product candidates delayed production products interrupted may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials manufacture sell products unable purchase sufficient quantities materials find suitable alternative materials timely manner development efforts product candidates may delayed ability manufacture sell products could limited suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control maintain full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand addition deliveries materials suppliers interrupted reason may unable ship certain products commercial supply supply product candidates development clinical trials also products materials utilize operations manufactured one supplier one facility may able replace timely manner commercially reasonable terms problems single suppliers facilities depend including event disaster earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials could adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability conduct clinical trials product candidates manufacture sell products could impaired regulatory legal risks operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries filed anticipate file marketing approval additional countries additional indications products next several years future marketing applications file may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use state certainty whether product candidates development approved launched whether able develop license acquire additional product candidates products whether products launched commercially successful manufacture sell products subject extensive regulation review example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk certain circumstances may required implement risk evaluation mitigation strategy program products could include medication guide patient package insert communication plan healthcare providers restrictions distribution use product elements fda deems necessary assure safe use drug discovery previously unknown problems marketed products product candidates including serious safety resistance drug interaction issues problems manufacturing safety reporting promotional activities may result regulatory approvals delayed denied granted significant restrictions products including limitations withdrawal products market failure comply requirements imposed fda could result significant civil monetary penalties fines suspensions regulatory approvals product recalls seizure products criminal prosecutions impacted evolving laws regulations legislative regulatory actions applicable health care industry health care industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting health care fraud abuse data privacy security united states laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute laws regulate written verbal communications products individual state laws relating pricing sales marketing practices health insurance portability accountability act federal state laws relating privacy security health information actual alleged violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state health care programs including medicare medicaid department veterans affairs department defense health programs actions executives overseeing business significant remediation measures negative publicity consequences laws regulations broad scope subject changing evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices resulting impact business uncertain could material addition government price reporting payment regulations complex continually assessing methods calculate report pricing accordance obligations methodologies calculations inherently subjective may subject review challenge various government agencies may disagree interpretation government disagrees reported calculations may need restate previously reported data could subject additional financial legal liability also continues enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement patient support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products description government investigations related litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report subject risks significant safety issues arise marketed products product candidates additional studies conducted subsequent obtaining marketing approval products products used longer periods time many patients including patients underlying health problems patients taking medicines expect continue finding new issues related safety resistance drug interactions issues may require changes product labels additional warnings contraindications even narrowed indications halt sales product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties patents proprietary rights important business part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report entry generic versions products may future lead market share price erosion found infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned third parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir well certain uses combinations emtricitabine ftc tenofovir disoproxil fumarate tdf taf description pending patent litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions could adversely affected trade secrets internal know technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions face potentially significant liability increased expenses litigation government investigations relating products operations involved number litigation investigation disputerelated matters require us expend substantial internal financial resources matters could require us pay significant monetary amounts including royalty payments past future sales example february reached agreement viiv healthcare company related parties collectively viiv global resolution pending potential claims related sales biktarvy pursuant viiv granted gilead broad worldwide license covenant sue relating past present future development commercialization bictegravir gilead agreed make onetime payment billion ongoing royalty rate future sales biktarvy bictegravir component bictegravircontaining products united states october expect matters continue require high level internal financial resources foreseeable future matters reduced expected continue reduce earnings require significant management attention addition testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise claims may exceed coverage description litigation investigation disputerelated matters see note commitments contingencies notes consolidated financial statements included part ii item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us operational risks business may future adversely affected outbreaks epidemic pandemic contagious diseases including ongoing covid outbreak actual threatened outbreaks epidemic pandemic contagious diseases covid may significantly disrupt global operations adversely affect business financial condition results operations example covid pandemic caused significant volatility uncertainty us international markets resulted increased risks adverse impacts operations including described addition developments discussed part ii item managements discussion analysis financial condition results operations monitoring number risks related pandemic including following supply chain pandemic could result disruptions global supply chain distribution future example quarantines shelterinplace governmental orders policies travel restrictions airline capacity route reductions safety guidelines health impacts pandemic could impact availability productivity products personnel manufacturers distributors freight carriers necessary components supply chain addition may unfavorable changes availability cost raw materials intermediates materials necessary production may result higher costs disruptions supply chain interruptions distribution capabilities clinical trials pandemic adversely affected may continue adversely affect certain clinical trials including ability initiate complete clinical trials within anticipated timelines ongoing trials clinical trial sites imposed restrictions patient visits limit risks possible covid exposure may experience issues participant compliance clinical trial protocols result quarantines travel restrictions interruptions healthcare services also risk closures clinical sites may necessary pandemic related guidance restrictions continue evolve foregoing reasons experienced delays new subject enrollment clinical trials course pandemic may continue experience overall delays clinical trials also risk biased data collection certain clinical trial sites remain open result challenges anticipated filing marketing timelines certain products may adversely impacted regulatory reviews operations fda ema regulatory agencies may adversely affected may also experience delays necessary interactions regulatory authorities around world including respect anticipated filing together factors resulting pandemic may adversely impact ability launch new commercial products access healthcare providers pandemic limited patients ability willingness access seek care healthcare providers initiate continue therapies resulted lower demand products course pandemic particularly respect hepatitis c virus hcv treatment hiv treatment prevention example observed lower levels patient visits testing volumes hcv resulting fewer patient starts addition times pandemic seen lower levels screening diagnosis hiv resulting fewer treatment initiations well higher levels discontinuations resulting reduction prescription refills increased levels unemployment times pandemic also experienced shifts payer mix towards governmentfunded coverage uninsured segment field personnel also reduced access healthcare personnel pandemic including fewer inperson interactions adversely impacted may continue adversely impact commercial activities employees face risks related health safety morale productivity employees including safe occupancy sites pandemic fourth quarter transitioned returntosite phase us flexible location employees job site enhancements risk protocols include health screenings covid testing vaccine requirements guarantee maintain continued safe occupancy sites may adversely impact employee recruitment retention onsite employees testing positive covid could lead mandatory quarantines potential site shutdowns financial pandemic may continue adverse financial impact short term potentially beyond particular hcv hiv businesses continue adversely impacted example observed reductions overall us hcv treatment hiv treatment hiv preexposure prophylaxis prep volumes times pandemic uncertain volumes return pre pandemic levels may continue experience fluctuating revenues infection rates rise fall pandemic restrictions periodically tightened eased also experienced may continue experience volatility shortterm revenues due fluctuations inventory channel purchases pandemic could also additional unexpected expenses related pandemic could negatively affect results operations factors together overall uncertainty disruption caused pandemic could result increased volatility decreased predictability results operations volatility stock price pandemic also amplified many risks described throughout risk factors section annual report extent pandemic impacts business results depend future developments uncertain predicted confidence including potential future waves pandemic new variants virus impact severity duration pandemic development distribution effectiveness public acceptance vaccines ongoing future actions taken contain pandemic face risks associated global operations global operations accompanied certain financial political economic risks including listed foreign currency exchange year ended december approximately product sales outside united states significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar hedging program eliminate exposure currency fluctuations may adversely impacted us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation interest rates inflation hold interestgenerating assets interestbearing liabilities including availableforsale debt securities senior unsecured notes credit facilities fluctuations interest rate could expose us increased financial risk addition changes inflation rate could also adversely impact business financial results antibribery subject us foreign corrupt practices act similar worldwide antibribery laws govern international operations respect payments government officials international operations heavily regulated require significant interaction foreign officials operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may statecontrolled manner different local custom possible certain practices may challenged laws addition internal control policies procedures may protect us reckless criminal acts committed employees agents enforcement activities antibribery laws could subject us administrative legal proceedings actions could result civil criminal sanctions including monetary penalties exclusion healthcare programs risks inherent conducting global business include restrictive government actions intellectual property foreign assets nationalization expropriation imposition compulsory licenses similar actions including waiver intellectual property protections protective economic policies taken foreign governments trade protection measures import export licensing requirements may result imposition trade sanctions similar restrictions united states governments business interruptions stemming natural manmade disasters climate change earthquakes hurricanes flooding fires extreme heat drought actual threatened public health emergencies efforts taken third parties prevent mitigate disasters public safety power shutoffs facility shutdowns may uninsured inadequately insured example corporate headquarters foster city certain rd manufacturing facilities located california seismically active region event major earthquake may carry adequate earthquake insurance significant recovery time could required resume operations political instability disruption geographic region operate regardless cause including war terrorism social unrest political changes aspirations goals disclosures related environmental social governance esg matters expose us numerous risks including risks reputation stock price institutional individual investors increasingly using esg screening criteria determine whether gilead qualifies inclusion investment portfolios frequently asked investors stakeholders set ambitious esg goals provide new robust disclosure goals progress toward goals matters interest esg stakeholders response adapted tracking reporting corporate responsibility program various evolving esg frameworks established announced goals objectives related esg matters goal statements reflect current plans aspirations guarantees able achieve efforts accomplish accurately report goals objectives present numerous operational reputational financial legal risks could material negative impact including reputation stock price ability achieve goal objective including respect environmental diversity initiatives subject numerous risks many outside control examples risks include availability cost low noncarbonbased energy sources technologies evolving regulatory requirements affecting esg standards disclosures availability suppliers meet sustainability diversity standards ability recruit develop retain diverse talent labor markets impact organic growth acquisitions dispositions businesses operations standards tracking reporting esg matters relatively new harmonized continue evolve selection disclosure frameworks seek align various reporting standards may change time time may result lack consistent meaningful comparative data period period addition processes controls may always comply evolving standards identifying measuring reporting esg metrics interpretation reporting standards may differ others standards may change time could result significant revisions goals reported progress achieving goals esg practices meet evolving investor stakeholder expectations standards reputation ability attract retain employees attractiveness investment business partner acquiror could negatively impacted similarly failure perceived failure pursue fulfill goals targets objectives satisfy various reporting standards within timelines announce could also similar negative impacts expose us government enforcement actions private litigation depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories example collaboration arrangements janssen sciences ireland uc odefsey compleraeviplera symtuza countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline due specialized technical nature business failure attract develop retain highly qualified personnel could adversely impact us future success depend large part continued ability attract develop retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization ability also depends part well maintain strong workplace culture attractive employees addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit face competition personnel companies universities public private research institutions government entities organizations additionally changes us immigration work authorization laws regulations could make difficult employees work transfer one jurisdictions operate significant cybersecurity incidents could give rise legal liability regulatory action data protection privacy laws adversely affect business operations dependent upon information technology systems infrastructure data including kite konnect platform critical maintain chain identity chain custody yescarta tecartus multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion ransomware attack likewise data privacy security breaches employees others result exposure sensitive data including intellectual property trade secrets personal information employees patients customers business partners unauthorized persons public cybersecurity incidents increasing frequency sophistication intensity including covid pandemic cybersecurity incidents include example deployment harmful malware ransomware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture like many companies experienced cybersecurity incidents including data breaches service interruptions cybersecurity incidents occur respond address accordance applicable governmental regulations legal requirements including cybersecurity protocols assurance efforts response cybersecurity incidents well investments protect information technology infrastructure data shield us significant losses potential liability prevent future interruption breach systems cybersecurity incidents cause loss critical sensitive information including personal information could give rise legal liability regulatory action data protection privacy laws regulators globally also imposing new data privacy security requirements including new greater monetary fines privacy violations example general data protection regulation gdpr established regulations regarding handling personal data noncompliance gdpr may result monetary penalties four percent worldwide revenue addition new domestic data privacy security laws california consumer privacy act california privacy rights act laws may passed similarly introduce requirements respect personal information noncompliance laws may result liability private actions subject statutorily defined damages event certain data breaches enforcement changes new laws regulations associated enhanced protection personal information including cases healthcare data personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate strategic financial risks subject risks associated engaging business acquisitions licensing arrangements collaborations options equity investments asset divestitures strategic transactions engaged may future engage transactions part business strategy may identify suitable transactions future may complete transactions timely manner costeffective basis may realize expected benefits successful making acquisition closing licensing arrangement collaboration products intellectual property technologies acquired licensed may successful may require significantly greater resources investments anticipated part annual impairment testing goodwill indefinitelived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles may need recognize impairment charges products intellectual property technologies acquired licensed successful option structured deals assurance elect exercise option right possible disagreements uncertainties circumstances may arise including respect whether option rights appropriately triggered may hinder ability realize expected benefits equity investments strategic transactions connection collaborations arcus biosciences inc galapagos nv value equity investments may fluctuate decline value successful execution implementation transactions financial condition cash flows results operations may adversely affected stock price could decline paid substantial amounts cash incurred additional debt finance strategic transactions additional indebtedness lower cash balance could result downgrade credit ratings limit ability borrow additional funds refinance existing debt favorable terms increase vulnerability adverse economic industry conditions reduce financial flexibility continue capital investments stock repurchases dividend payments example result cash used debt issued connection acquisition immunomedics inc sp global ratings downgraded credit rating may adversely impacted failure overcome additional risks changes effective income tax rate could reduce earnings subject income taxes united states various foreign jurisdictions due economic political conditions various countries actively considering made changes existing tax laws predict form timing changes effective tax rates affected changes mix earnings countries differing statutory tax rates changes valuation deferred tax assets liabilities introduction new taxes changes tax laws regulations administrative practices interpretations including united states germany ireland also subject examination tax returns tax matters us internal revenue service tax authorities various foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions may adversely affected resolution one exposures reporting period item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also rd facilities emeryville oceanside santa monica california seattle washington morris plains new jersey frederick maryland edmonton canada dublin ireland principal manufacturing facilities el segundo la verne oceanside san dimas california edmonton canada cork ireland hoofddorp netherlands information manufacturing facilities see item business manufacturing facilities global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites adequate suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild february approximately stockholders record common stock performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed securities exchange commission sec incorporated reference filings securities act amended securities act securities exchange act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested equity compensation plan information following table provides certain information respect equity compensation plans effect december number common shares remaining available future number common shares weightedaverage issuance equity issued upon exercise exercise price compensation plans outstanding options warrants outstanding options excluding securities millions except per share amounts rights warrants rights reflected column plan category b c equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total take account million restricted stock units performance share awards units phantom shares exercise price granted equity incentive plans includes awards shares previously issuable immunomedics inc amended restated longterm incentive plan immunomedics plan assumed connection acquisition immunomedics inc subsequently merged equity incentive plan employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable includes awards shares issuable forty seven inc equity incentive plan assumed connection acquisition forty seven inc forty seven subsequently amended restated equity incentive plan material features gilead sciences inc equity incentive plan forty seven inc equity incentive plan originally established forty seven june connection gileads acquisition forty seven april gilead assumed forty seven inc equity incentive plan amended restated gilead sciences inc equity incentive plan plan plan intended help gilead secure retain services eligible award recipients provide incentives persons exert maximum efforts success gilead affiliate provide means eligible recipients may benefit increases value gilead common stock april employees consultants forty seven immediately prior date employees consultants gilead hired following date eligible receive grants new awards plan plan provides award incentive stock options nonqualified stock options must generally exercise price equal least fair market value common stock date grant stock appreciation rights restricted stock awards restricted stock unit awards performance stock awards stock awards performance cash awards april aggregate number shares common stock issuable plan date april gilead granted restricted stock units performance share awards units stock options plan types equity awards outstanding plan december million shares gilead common stock remained available issuance plan issuer purchases equity securities first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions made repurchases program starting april first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions repurchased retired million shares common stock million open market transactions program december remaining authorized repurchase amount programs billion table summarizes stock repurchase activity three months ended december maximum fair total number value shares total number average shares purchased may yet shares price paid part publicly purchased purchased per share announced program programs thousands dollars thousands millions october october november november december december total difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations dividends years ended december paid quarterly dividends expect continue pay quarterly dividends although amount timing future dividends subject declaration board directors additional information included item managements discussion analysis financial condition results operations consolidated financial statements item reserved item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures part item risk factors additional information related comparison results operations years included item managements discussion analysis financial condition results operations filed us securities exchange commission sec consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approved united states also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements business highlights delivered strong financial performance veklury continued play critical role addressing coronavirus disease covid pandemic veklurys performance helped mitigate impacts covid parts business including hiv chronic hepatitis c virus hcv franchises impacts october loss exclusivity truvada atripla united states despite transitory headwinds underlying demand virology portfolio remained strong led continued growth biktarvy franchise also received increased contributions oncology franchise experiencing growth trodelvy well cell therapy franchise continued expand strengthen commercial portfolio clinical pipeline across therapeutic focus areas drive future growth potential announced additional six filings regulatory approval addition investing internal pipeline programs also continued enter leverage existing strategic collaborations partnerships including opting four additional pipeline assets collaboration arcus biosciences inc arcus develop foundation sustainable diversified business viral diseases october us food drug administration fda approved new lowdose tablet dosage form biktarvy pediatric patients weighing least kg less kg virologically suppressed new antiretroviral therapy august marketing authorization application lenacapavir investigational longacting hiv capsid inhibitor fully validated evaluation european medicines agency ema june fda granted approval new oral pellet formulation epclusa expanding pediatric indication treat children young years age chronic hcv june submitted new drug application fda lenacapavir investigational longacting agent development treatment hiv people limited therapy options march entered agreement merck sharp dohme corp merck subsidiary merck co inc jointly develop commercialize longacting investigational treatments hiv combine gileads investigational capsid inhibitor lenacapavir mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir march completed acquisition myr gmbh myr acquisition provides us hepcludex conditionally approved ema treatment chronic hepatitis delta virus hdv adults compensated liver disease covid january fda granted expedited approval veklury treatment nonhospitalized adult adolescent patients high risk progression severe covid including hospitalization death december european commission granted approval expand indication veklury use earlier stages disease adult patients require supplemental oxygen increased risk progressing severe covid april announced provide assistance support expansion local manufacturing capacity remdesivir india donate active pharmaceutical ingredient ii donate minimum vials veklury remdesivir government india oncology cell therapy january fda approved update prescribing information yescarta include use prophylactic corticosteroids across approved indications yescarta first chimeric antigen receptor car tcell therapy information label help physicians manage potentially prevent treatment side effects october fda approved tecartus treatment adult patients relapsed refractory bcell precursor acute lymphoblastic leukemia tecartus first car cell therapy approved adults september kite gilead company kite submitted supplemental biologics license application fda yescarta expand current indication include treatment adults relapsed refractory large bcell lymphoma lbcl secondline setting august kite appia bio inc entered collaboration license agreement research develop hematopoietic stem cell derived cell therapies directed toward hematological malignancies june kite entered research collaboration license agreement shoreline biosciences inc develop novel allogeneic cell therapies across variety cancer targets june fosun kite biotechnology co ltd joint venture kite shanghai fosun pharmaceutical group co ltd received approval china national medical products administration axicabtagene ciloleucel treatment adult patients relapsed refractory lbcl china march fda granted accelerated approval yescarta treatment adult patients relapsed refractory follicular lymphoma fl january entered clinical trial collaboration agreement merck evaluate trodelvy combination mercks antiprogrammed death receptor pd therapy keytruda firstline setting patients nonsmall cell lung cancer nsclc november european commission granted marketing authorization trodelvy treatment metastatic triplenegative breast cancer tnbc adult patients unresectable metastatic tnbc received two prior systemic therapies least one advanced disease november exercised options three programs clinicalstage portfolio arcus including antitigit molecules domvanalimab ab well clinical candidates etrumadenant dual adenosine aaab receptor antagonist quemliclustat small molecule cd inhibitor transaction closed december october entered clinical trial collaboration supply agreement merck evaluate efficacy trodelvy combination keytruda firstline treatment patients locally advanced metastatic tnbc september health canada approved trodelvy treatment adult patients unresectable locally advanced metastatic tnbc received two therapies least one metastatic disease canada joined australia great britain switzerland united states among countries approved trodelvy use project orbis global collaborative review program high impact oncology marketing applications across participating countries april fda granted accelerated approval trodelvy use adult patients locally advanced metastatic urothelial cancer uc new indication april fda granted full approval trodelvy adult patients unresectable locally advanced metastatic tnbc announced discussed updates detail press releases available website wwwgileadcom readers also encouraged review press releases available website mentioned content referenced websites constitute part incorporated reference annual report form k financial highlights millions except percentages per share amounts change total revenues net income attributable gilead nm net income per share attributable gilead common stockholders diluted nm nm meaningful total revenues increased billion compared billion primarily due increased sales veklury fdaapproved treatment hospitalized patients covid increase also reflects continued growth biktarvy geographies continued uptake trodelvy cell therapy chronic hepatitis b virus hbv hdv products increases partially offset decrease truvada atripla sales united states expected primarily due continued generic competition following october loss exclusivity united states net income attributable gilead billion diluted earnings per share compared million diluted earnings per share increase primarily due lower acquired inprocess research development iprd charges revenue growth lower unrealized losses equity investments partially offset billion charge settlement related bictegravir litigation charge million related arcus collaboration optin acquired iprd expenses billion primarily related acquisition forty seven well collaborations investments entered year arcus pionyr immunotherapeutics inc pionyr tango therapeutics inc tango tizona therapeutics inc tizona jounce therapeutics inc jounce strategy outlook purpose deliver lifechanging medications patients need scientific breakthroughs innovation strong operational execution strategic ambitions bring transformative therapies patients ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priorities reflect deliver ambitions expand internal external innovation ii strengthen portfolio strategy decision making iii increase patient benefit access iv continue evolve culture continue focus executing strategy expand diversify commercial portfolio clinical pipelines across three therapeutic focus areas virology oncology inflammation specifically plan significantly increase clinical development studies across novel oncology portfolio maintaining leadership antiviral medications work hiv hepatitis covid pandemic emerging viruses collaboration arcus provides additional opportunities us develop foundation sustainable diversified business beyond expanding products pipeline also continue focus employees evolution culture efforts promote racial equity social justice additionally expect maintain rigorous focus disciplined expense management covid pandemic continues impact business broader market dynamics expect revenue growth product sales excluding veklury compared hiv product sales continue recover covid pandemic demonstrate yearoveryear growth financial impact truvada atripla loss exclusivity largely behind us starting second quarter also expect oncology businesses including cell therapy trodelvy contribute growth veklury sales generated highly dynamic complex global environment continues evolve result veklury sales subject significant volatility uncertainty future product demand depend nature covid pandemic including duration infection rates hospitalizations availability adoption alternative therapies vaccines anticipate yearoveryear decline veklury product sales expect veklury continue play key role pandemic contribute meaningfully revenue heavily weighted towards beginning year ability deliver strategy subject number uncertainties including limited effects covid pandemic remains unpredictable uncertainty regarding amount timing future veklury sales continuation uncertain global macroeconomic environment ability realize potential benefits acquisitions collaborations licensing arrangements ability initiate progress complete clinical trials within currently anticipated timeframes including result current future holds clinical trials possibility unfavorable results new ongoing clinical trials ability submit new drug applications new product candidates expanded indications currently anticipated timelines ability receive regulatory approvals timely manner market share price erosion caused introduction generics loss exclusivity products higher anticipated effects loss exclusivity truvada atripla slower anticipated growth biktarvy trodelvy vemlidy cell therapy products inaccuracies patient start estimates additional pricing pressures payers competitors increase discounts chargebacks rebates due ongoing contracts future negotiations commercial government payers potential government actions could effect lowering prices largerthan anticipated shift payer mix highly discounted payer segment volatility foreign currency exchange rates results operations revenues following table summarizes periodoverperiod changes revenues year ended december year ended december millions except percentages us europe international total us europe international total change product sales hiv veklury hcv hbvhdv cell therapy trodelvy nm total product sales royalty contract revenues total revenues nm meaningful product sales hiv hiv product sales decreased billion compared billion due anticipated decline sales volume truvada emtricitabine ftc tenofovir disoproxil fumarate tdfbased products driven continued generic competition following october loss exclusivity truvada atripla united states truvada atripla product sales billion lower compared decrease also impacted lower sales genvoya driven decrease volume worldwide primarily due patients switching biktarvy declines partially offset increase biktarvy product sales worldwide driven higher demand higher net average selling price driven favorable changes estimates government rebates discounts united states expect hiv business continue recover covid pandemic also expect impact truvada atripla loss exclusivity largely behind us starting second quarter veklury veklury product sales billion compared billion veklury became commercially available third quarter resulting partial year sales increase also attributable higher hospital demand worldwide sales veklury generally affected covid related rates infections hospitalizations vaccinations well availability uptake effectiveness alternative treatments covid result future sales veklury difficult predict hcv hcv product sales decreased billion compared billion primarily due lower demand driven fewer patient starts worldwide due impact covid pandemic slight increase hcv sales europe due favorable change estimate government rebates offset revenue decrease associated lower demand hbv hdv hbv hdv product sales increased million compared million primarily due higher vemlidy product sales due higher demand geographies partially offset lower viread product sales international locations hepcludex sales million launch activities continued across europe following first quarter acquisition myr cell therapy cell therapy product sales include yescarta tecartus increased million compared million growth primarily due july launch tecartus united states treatment adult patients relapsed refractory mantle cell lymphoma mcl december launch tecartus mcl europe resulting partial year sales increase also driven continued higher demand yescarta worldwide lbcl volume growth related approval yescarta fl united states trodelvy trodelvy product sales increased million compared million obtained trodelvy fourth quarter acquisition immunomedics resulting partial year sales addition revenues include continued uptake trodelvy following full regulatory approval metastatic tnbc united states europe accelerated approval metastatic uc united states product sales product sales include ambisome cayston jyseleca letairis ranexa zydelig billion remained flat compared ambisome sales volume increased due higher demand geographies outside united states increase mostly offset lower letairis sales united states anticipated due continued generic competition following loss exclusivity grosstonet deductions record product sales net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales returns related costs deductions totaled billion gross product sales compared billion gross product sales reduction driven changes product mix primarily due higher veklury sales billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees sales returns related costs foreign currency exchange impact total product sales generated outside united states respectively generally face exposure movements foreign currency exchange rates primarily euro use foreign currency exchange contracts hedge portion foreign currency exposures foreign currency exchange net hedges favorable impact total product sales million based comparison using foreign currency exchange rates largely driven eurobased product sales following table summarizes periodoverperiod changes product sales year ended december year ended december millions except percentages us europe international total us europe international total change hiv products descovy ftctaf based products biktarvy descovy genvoya odefsey revenue share symtuza total descovy ftctaf based products truvada ftctdf based products atripla compleraeviplera stribild truvada total truvada ftctdf based products hiv total hiv veklury hcv products ledipasvirsofosbuvir sofosbuvirvelpatasvir hcv total hcv hbvhdv products vemlidy viread hbvhdv nm total hbvhdv cell therapy products tecartus nm yescarta total cell therapy trodelvy nm products ambisome letairis ranexa zydelig total total product sales nm meaningful represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company includes emtriva tybost amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes hepcludex hepsera includes cayston jyseleca costs expenses following table summarizes periodoverperiod changes costs expenses millions except percentages change cost goods sold product gross margin bps research development rd expenses acquired iprd expenses selling general administrative sga expenses product gross margin product gross margin decreased compared primarily due billion charge settlement related bictegravir litigation well increase million acquisitionrelated expenses amortization finitelived intangible assets recognition inventory stepup charges primarily driven acquisitions immunomedics myr product gross margin also impacted higher inventory writedown charges changes product mix increases partially offset lower royalty expenses due lower sales products containing emtricitabine elvitegravir reversal previously recorded million litigation accrual following favorable court decision related axicabtagene ciloleucel research development expenses rd expenses consist primarily clinical studies performed contract research organizations materials supplies payments collaborative arrangements including milestone payments licenses fees expense reimbursements collaboration partners personnel costs including salaries benefits stockbased compensation expense overhead allocations consisting various support infrastructure costs manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability technical regulatory successful development market potential available human capital resources considerations continually review rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities believe best support longterm growth business rd expenses increased million compared primarily due arcus collaboration optin charge million well higher investments trodelvy magrolimab clinical activities increases partially offset decline approximately million external expenses related winddown completion certain remdesivir clinical studies ii million million charge recorded connection agreement amend existing arrangement galapagos commercialization development jyseleca iii lower stockbased compensation expense rd expenses included accelerated stockbased compensation expenses million related acquisitions immunomedics forty seven acquired inprocess research development expenses acquired iprd expenses reflect iprd impairments well initial costs externally developed iprd projects acquired directly transaction business combination alternative future use including upfront payments related various collaborations initial costs rights iprd projects acquired iprd expenses million related licensing collaboration investment arrangements entered year acquired iprd expenses billion primarily related acquisition forty seven well collaborations investments entered year arcus pionyr tango tizona jounce selling general administrative expenses sga expenses relate sales marketing finance human resources legal administrative activities including information technology investments sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales sga expenses increased million compared primarily due expense million related donation certain equity securities fair value gilead foundation california nonprofit organization foundation increased commercial activities including higher promotional marketing activities primarily driven trodelvy sga expenses included accelerated stockbased compensation expense million related acquisitions immunomedics forty seven charge million related us department justice investigation settled third quarter interest expense income expense net following table summarizes periodoverperiod changes interest expense income expense net millions except percentages change interest expense income expense net interest expense increased million compared primarily due increase borrowing related fourth quarter acquisition immunomedics partially offset lower interest expense due debt maturities repayments changes income expense net compared primarily reflects lower unrealized losses fair value adjustments investments equity securities largely driven investment galapagos partially offset lower interest income changes fair value equity securities resulted net unrealized losses million billion years ended december respectively income taxes following table summarizes periodoverperiod changes income tax expense benefit millions except percentages income income taxes income tax expense effective tax rate effective tax rate decreased compared primarily due billion acquired iprd charge recorded connection acquisition forty seven million certain acquired iprd charges nondeductible tax purposes liquidity capital resources cash cash equivalents marketable debt securities billion billion december respectively cash flows following table summarizes cash flow activities millions net cash provided used operating activities investing activities financing activities operating activities cash provided operating activities represents cash receipts disbursements related activities investing financing activities operating cash flow derived adjusting net income noncash items changes operating assets liabilities cash provided operating activities increased billion billion compared increase primarily due revenue growth sales veklury well higher collection receivables investing activities cash used investing activities primarily consists purchases sales maturities marketable debt securities capital expenditures acquisitions including iprd net cash acquired purchases equity securities investments cash used investing activities billion compared billion decrease cash used investing activities primarily due decrease cash outflows related acquisitions including iprd net cash acquired made billion payment first quarter acquisition myr compared billion billion payments made related acquisitions forty seven immunomedics respectively decrease partially offset net cash generated investing activities related proceeds sales maturities marketable debt securities used partially fund acquisitions financing activities cash used financing activities year ended december billion compared cash provided financing activities million utilized cash billion debt repayments billion dividend payments million common stock repurchases obtained billion proceeds debt financing net issuance costs fund fourth quarter acquisition immunomedics partially offset cash utilized billion dividend payments billion debt repayments billion common stock repurchases debt credit facilities summary borrowings various financing arrangements included note debt credit facilities notes consolidated financial statements included item annual report may choose repay certain longterm debt obligations prior maturity dates based assessment current longterm liquidity capital requirements senior unsecured notes term loan repaid billion debt consisting billion senior unsecured notes billion senior unsecured term loan facility repaid billion senior unsecured notes due april first quarter billion senior unsecured notes due december third quarter additionally repaid million senior unsecured notes due upon maturity september october exercised option call million senior unsecured floating rate notes million senior unsecured notes final maturity date september two early repayments totaling billion principal amount made fourth quarter december exercised option call million senior unsecured notes final maturity march notes repaid february new debt issued required comply certain covenants note indentures governing senior unsecured notes december violation covenants liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi finance trust prior acquisition immunomedics liability related future royalties primarily included longterm debt net consolidated balance sheets see note acquisitions notes consolidated financial statements included item annual report form k additional information credit facility june terminated billion fiveyear revolving credit facility maturing may revolving credit facility entered new billion fiveyear revolving credit facility maturing june revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facility revolving credit facility contains customary representations warranties affirmative negative covenants events default december compliance covenants capital return program details stock repurchase programs dividends included note stockholders equity notes consolidated financial statements included item annual report stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions purchased million million shares common stock program million billion respectively december remaining authorized repurchase amount programs billion dividends declared paid quarterly cash dividends aggregate amount billion per share common stock billion per share common stock respectively february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors capital resources believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms material cash requirements continually evaluate liquidity capital resources including access external capital ensure adequately efficiently finance operations december material cash requirements consisted primarily repayment outstanding borrowings remaining obligations onetime repatriation transition tax tax cuts jobs act settlement related bictegravir litigation purchases inventory operating leases obligations capital expenditures milestone payments related collaborative agreements see notes collaborations arrangements debt credit facilities leases commitments contingencies income taxes notes consolidated financial statements included item annual report additional information anticipate cash requirements related capital expenditures increase compared prior year work expand site infrastructure capabilities critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements included item annual report prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements government rebates chargebacks revenues product sales recognized net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related deductions deductions product sales referred grosstonet deductions estimated recorded period related product sales occur revenues product sales net deductions recorded extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated grosstonet deductions subsequently resolved government rebates chargebacks subject complex estimation process requires significant judgment management part due lag date product sales date related rebates chargeback claims settled government rebates chargebacks include amounts payable payers healthcare providers various programs may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price rebates chargebacks estimated primarily based product sales expected payer mix discount rates require significant estimates judgment additionally developing estimates government rebates chargebacks consider following historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information following table summarizes consolidated activities ending balances government rebates chargebacks accounts balance decreaseincrease balance end millions beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total product sales include impact million changes estimates related product sales primarily united states assumed higher rebate claims government payer segments resulting part covid pandemic anticipated impacts materialize assess update estimates reporting period reflect actual claims current information believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates historically actual government rebates chargebacks claimed prior periods varied less estimates government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets totaled million million december respectively see note financial information notes consolidated financial statements included item annual report additional information government rebates payable third party payers healthcare providers generally recorded accrued government rebates consolidated balance sheets totaled billion billion december respectively acquisitions valuation intangibles make certain judgments determine whether transactions accounted acquisitions assets business combinations determined substantially fair value gross assets acquired transaction concentrated single asset group similar assets transaction treated acquisition assets evaluate inputs processes outputs associated acquired set activities assets assets transaction include input substantive process together significantly contribute ability create outputs transaction treated acquisition business account business combinations using acquisition method accounting requires assets acquired liabilities assumed generally recorded fair values acquisition date excess consideration fair value net assets acquired recorded goodwill estimating fair value requires us make significant judgments assumptions perform impairment testing goodwill annually frequently events changes circumstances indicate likely asset impaired transactions accounted acquisitions assets goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date expensed unless alternative future use addition product development milestones expensed upon achievement valuation intangible assets acquired expect continue acquire intangible assets asset acquisitions business combinations identifiable intangible assets measured respective fair values acquisition date intangible assets acquired business combinations subject potential adjustments within measurement period may one year acquisition date fair values intangible assets generally determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets require use significant estimates assumptions including limited identification product candidates sufficient substance requiring separate recognition estimates projected future cash flows including revenues operating profits related products product candidates probability technical regulatory success unapproved product candidates considering stages development time resources needed complete development approval product candidates appropriate discount rate life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired based upon reasonable estimates assumptions given facts circumstances related valuation dates impairment amortization intangible assets intangible assets related iprd projects acquired business combination capitalized indefinitelived intangible assets completion abandonment associated rd efforts period assets considered indefinitelived amortized development successfully completed generally occurs regulatory approval obtained associated assets deemed finitelived amortized respective estimated useful lives beginning point time primarily straightline basis indefinitelived intangible assets composed iprd projects acquired business combination lack regulatory approval time acquisition tested impairment annually whenever events changes circumstances indicate likely assets impaired upon regulatory approval estimates fair value result complex series judgments future events uncertainties make assumptions point time acquisition date subsequent impairment assessment date changes estimates assumptions including timing product launch pricing reductions failure obtain anticipated regulatory approval deterioration us global financial markets unanticipated events circumstances may decrease projected cash flows increase discount rate could potentially result impairment charge eventual realized value acquired iprd project may vary fair value date acquisition carrying value intangible asset exceeds estimated fair value impairment charge recorded write intangible asset estimated fair value example recognized million impairment charge related iprd projects primarily treatment indolent bcell nonhodgkin lymphoma due changes estimated market opportunities high rate failure inherent discovery development new products intangible assets also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration amortization see note goodwill intangible assets notes consolidated financial statements included item annual report additional information legal contingencies party various legal actions significant described note commitments contingencies notes consolidated financial statements included item annual report possible determine outcome matters recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible disclose possible loss range loss amount loss estimated time significant judgment required determination probability determination whether exposure reasonably estimable inherent uncertainty unpredictability related matters accruals based believe best information available time assessment including legal facts circumstances case status proceedings applicable law views legal counsel upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes fourth quarter recorded accrual billion accrued current liabilities consolidated balance sheets settlement related bictegravir litigation see note commitments contingencies notes consolidated financial statements included item annual report additional information income taxes estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization deferred tax assets reporting period record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes recognize tax benefit uncertain tax position likely tax position sustained upon examination tax authorities based technical merits position tax benefit recognized consolidated financial statements particular tax position based largest benefit likely realized amount unrecognized tax benefits utb adjusted appropriate changes facts circumstances significant amendments existing tax law new regulations interpretations tax authorities new information obtained tax examination resolution examination recognize accrued interest penalties appropriate related utb income tax expense benefit consolidated statements income recent accounting pronouncements new accounting pronouncements issued adopted year ended december significance us item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks market prices reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations countries worldwide result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million million respectively realized would negatively affected earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale debt securities senior unsecured notes create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december expected maturity total fair millions except percentages thereafter total value assets availableforsale debt securities average interest rate liabilities senior unsecured fixed rate notes including current portion average interest rate amounts represent principal balances addition senior unsecured fixed rate notes billion fiveyear revolving credit facility matures june amounts outstanding fiveyear revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information market price risk hold shares common stock certain publicly traded biotechnology companies primarily connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings fair value equity securities approximately billion billion december respectively changes fair value equity securities impacted volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increased decreased fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm pcaob id audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income loss consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate government commercial rebates description matter fully described note company estimates reductions revenues amounts payable payers healthcare providers united states various government commercial rebate programs period related sales occur rebates may vary product payer individual payer plans may known point sale estimated reductions revenue based product sales historical expected payer mix discount rates various estimated actual data adjusted current period expectations auditing companys estimated reductions revenue rebates complex involved significant judgment particularly assessing reasonableness estimated payer mix applied sales period estimate relies heavily historical data adjusted changes payer mix expectations time addressed evaluated tested design operating effectiveness companys internal controls managements estimation matter audit review reductions revenue rebate programs including controls assess payer mix assumption also tested completeness accuracy data utilized controls accuracy calculations supporting managements estimates test managements estimation methodology determining payer mix audit procedures included among others analytically evaluating managements estimates evaluating evidence contrary estimated amounts performing sensitivity analysis rates used estimates performing comparison actual payments related amounts accrued current prior years valuation inprocess research development intangible assets acquired immunomedics inc description matter december companys inprocess research development iprd intangible assets acquired connection acquisition immunomedics inc billion discussed note intangible assets indefinite useful lives related purchased iprd projects measured respective fair values acquisition date considered indefinitelived completion abandonment associated rd efforts company tests indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts auditing impairment test iprd intangible assets acquired immunomedics complex due significant judgment required estimating fair values particular fair value estimates required use valuation methodologies sensitive significant assumptions eg discount rate probability technical regulatory success addressable patient population treatment duration projected market share affected expected future market economic conditions addressed evaluated tested design operating effectiveness companys internal controls determination matter audit estimated fair value iprd intangible assets acquired immunomedics example tested controls management 's review valuation methodologies significant assumptions used develop fair value estimates also tested management 's controls validate data used fair value estimates complete accurate test estimated fair value company 's iprd intangible assets acquired immunomedics audit procedures among others included evaluating company 's use appropriate valuation methodologies assistance valuation specialist evaluating sensitivity analyses determine assumptions greatest impact overall determination value testing completeness accuracy underlying data audit procedures significant assumptions included comparing assumptions current industry market economic trends historical results company 's business guideline companies within industry relevant factors example evaluated probability technical regulatory success considering phase development clinical projects company 's history obtaining regulatory approval addition evaluated expected addressable patient populations comparing companys estimates external industry forecasts ernst young llp served companys auditor since san jose california february gilead sciences inc consolidated balance sheets december millions except per share amounts assets current assets cash cash equivalents shortterm marketable debt securities accounts receivable net inventories prepaid current assets total current assets property plant equipment net longterm marketable debt securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued current liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable deferred tax liability longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding december additional paidin capital accumulated comprehensive income loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income year ended december millions except per share amounts revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses acquired inprocess research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income income taxes income tax expense benefit net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted see accompanying notes gilead sciences inc consolidated statements comprehensive income loss year ended december millions net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt securities net unrealized gain loss net tax reclassifications net income net tax net change cash flow hedges net unrealized gain loss net tax reclassifications net income net tax net change comprehensive income loss comprehensive income loss comprehensive loss attributable noncontrolling interest comprehensive income loss attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity gilead stockholders equity accumulated common stock additional total paidin comprehensive retained noncontrolling stockholders millions except per share amounts shares amount capital income loss earnings interest equity balance december cumulative effect adoption new accounting standards net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december cumulative effect adoption new accounting standard change noncontrolling interest net income loss comprehensive income loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december net income loss comprehensive income loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december see accompanying notes gilead sciences inc consolidated statements cash flows year ended december millions operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes net gain loss equity securities acquired inprocess research development expenses inprocess research development impairment writedowns slowmoving excess raw material work process inventory changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable debt securities proceeds sales marketable debt securities proceeds maturities marketable debt securities acquisitions including inprocess research development net cash acquired purchases equity securities capital expenditures net cash used investing activities financing activities proceeds debt financing net issuance costs proceeds issuances common stock repurchases common stock repayments debt obligations payment dividends net cash used provided financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approved united states also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties assess whether primary beneficiary variable interest entity vie inception arrangement reporting date assessment based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie material vies december certain reclassifications made prior periods consolidated financial statements accompanying notes conform current presentation beginning acquired inprocess research development iprd expenses reported separately research development expenses consolidated statements income consolidated statements income year ended december conformed separately present acquired iprd expenses segment information one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need chief executive officer chief operating decisionmaker codm manages allocates resources operations company entitywide basis managing allocating resources entitywide basis enables codm assess overall level resources available best deploy resources across functions research development rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities best support longterm growth business see note revenues summary disaggregated revenues product geographic region significant accounting policies estimates judgments preparation consolidated financial statements accordance us generally accepted accounting principles requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various marketspecific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources estimates assessed period updated reflect current information economic considerations related impact coronavirus disease covid could significant accounting estimates actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party revenues recognized net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related deductions deductions product sales referred grossto net deductions estimated recorded period related product sales occur payment terms customers generally range days however payment terms differ jurisdiction customer instances type product revenues product sales net grosstonet deductions recorded extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated grosstonet deductions subsequently resolved taxes assessed governmental authorities collected customers excluded product sales expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects financing component grosstonet deductions rebates chargebacks government rebates chargebacks include amounts payable payers healthcare providers various programs may vary product payer individual payer plans rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price rebates chargebacks estimated primarily based product sales expected payer mix discount rates require significant estimates judgment additionally developing estimates consider historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information assess update estimates reporting period reflect actual claims current information government chargebacks payable direct customers generally classified reductions accounts receivable consolidated balance sheets government rebates payable third party payers healthcare providers recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales allowance sales returns allowances made estimated sales returns customers recorded period related revenue recognized typically permit returns product damaged defective otherwise used customer united states typically permit returns six months prior one year product expiration date outside united states returns allowed certain countries limited basis estimates sales returns based primarily analysis historical product return patterns industry information reporting return rates similar products contractual agreement terms also take consideration known expected changes marketplace specific product shipping handling shipping handling activities considered fulfillment activities considered separate performance obligation royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur research development expenses rd expenses consist primarily clinical studies performed contract research organizations cros materials supplies payments collaborative arrangements including milestone payments licenses fees expense reimbursements collaboration partners personnel costs including salaries benefits stockbased compensation expense overhead allocations consisting various support infrastructure costs milestone payments made thirdparty collaborators expensed incurred point regulatory approval milestone payments made upon regulatory approval capitalized amortized remaining useful life related product time time enter development collaboration agreements share expenses collaborative partner record payments received collaborative partners share development costs reduction rd expenses charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination payments make rd services prior services rendered recorded prepaid assets consolidated balance sheets expensed services provided acquired inprocess research development expenses acquired iprd expenses reflect iprd impairments well initial costs externally developed iprd projects acquired directly transaction business combination alternative future use including upfront payments related various collaborations initial costs rights iprd projects acquired iprd expensed acquisition date future costs develop iprd projects recorded research development expenses consolidated statements income incurred selling general administrative expenses selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales expense costs advertising including promotional expenses incurred advertising expenses million million million years ended december respectively cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable nonmarketable securities marketable debt securities determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date marketable debt securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable debt securities longterm marketable debt securities unrealized gains losses availableforsale debt securities excluded net income reported accumulated comprehensive income loss aoci separate component stockholders equity income expense net includes interest amortization purchase premiums discounts realized gains losses sales securities expected credit losses cost securities sold based specific identification method regularly review investments declines fair value amortized cost basis determine whether impairment due creditrelated factors noncreditrelated factors review includes creditworthiness security issuers severity unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost bases determine portion unrealized loss due expected credit loss recognize loss amount income expense net corresponding allowance carrying value security hold portion unrealized loss related factors credit losses recognized aoci marketable nonmarketable equity securities investments equity securities equity method investments recorded fair market value fair value readily determinable unrealized gains losses included income expense net consolidated statements income investments entities significant influence meet requirements consolidation elected fair value option use equity method accounting share underlying income loss entities reported income expense net consolidated statements income elected fair value option account equity investments arcus biosciences inc arcus galapagos nv galapagos significant influence believe fair value option best reflects underlying economics investments see note collaborations arrangements additional information equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer certain investments equity securities nonpublic companies accounted using equity method based ownership percentage factors indicate significant influence investee see note collaborations arrangements additional information investments equity securities recorded prepaid current assets longterm assets consolidated balance sheets regularly review securities indicators impairment concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment credit losses estimates allowance credit losses consider number factors including existing contractual payment terms individual customer circumstances historical payment patterns customers review local economic environment potential impact expected future customer payment patterns government funding reimbursement practices majority trade accounts receivable arises product sales united states europe additions allowance credit losses writeoffs recoveries customer receivables material years ended december inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slowmoving excess otherwise unsaleable items obsolete slowmoving excess unsaleable items observed alternate uses inventory record writedown net realizable value charge cost goods sold consolidated statements income determination net realizable value requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors considered including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term leases determine arrangement contains lease inception rightofuse assets lease liabilities recognized commencement date based present value lease payments lease term noncancelable period stated contract adjusted options extend terminate reasonably certain exercise option rightofuse assets adjusted prepaid lease payments lease incentives initial direct costs incurred operating lease expense minimum lease payments recognized straightline basis lease term account lease nonlease components lease agreements single lease component determining lease assets liabilities addition recognize rightofuse assets liabilities leases lease terms one year less operating leases provide implicit interest rate generally utilize collateralized incremental borrowing rate applied portfolio approach relevant based information available commencement date determine lease liability acquisitions account business combinations using acquisition method accounting generally requires assets acquired including iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess consideration fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period may one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred determine net assets acquired meet definition business combination acquisition method accounting transaction accounted acquisition assets therefore goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date subsequent milestone payments expensed incurred consolidated statements income unless alternative future use goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets measured respective fair values acquisition date may subject adjustment within measurement period may one year acquisition date intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts amortize goodwill intangible assets indefinite useful lives goodwill indefinitelived intangible assets tested impairment annually frequently events changes circumstances indicate likely assets impaired development successfully completed generally occurs regulatory approval obtained associated assets deemed finitelived amortized respective estimated useful lives beginning point time intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances indicate carrying value assets may recoverable impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may indicate carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset carrying amount asset asset group asset asset group determined impaired excess carrying value asset asset group estimated fair value recognized impairment loss valuation contingent consideration resulting business combination connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date reporting period thereafter revalue obligations record increases decreases fair value research development expenses consolidated statements income time related product candidate receives marketing approval increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component aoci within stockholders equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains losses material years ended december hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes fair value financial instruments apply fair value accounting financial nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets unrealized changes fair value derivatives designated part hedge transaction recorded aoci unrealized gains losses aoci reclassified product sales consolidated statements income respective hedged transactions affect earnings changes fair value derivatives part hedge transaction recorded period income expense net consolidated statements income assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income sharebased compensation provide sharebased compensation form various types equitybased awards including restricted stock units rsus performance share awards units psus stock options compensation expense recognized consolidated statements income based estimated fair value award grant date estimated fair value rsus based closing price common stock psus depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant stock option awards estimated fair value based blackscholes option valuation model contingencies party various legal actions recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible disclose possible loss range loss amount loss estimated time income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations recognize tax benefit uncertain tax position likely tax position sustained upon examination tax authorities based technical merits position tax benefit recognized consolidated financial statements particular tax position based largest benefit likely realized amount unrecognized tax benefits utb adjusted appropriate changes facts circumstances significant amendments existing tax law new regulations interpretations tax authorities new information obtained tax examination resolution examination recognize accrued interest penalties appropriate related utb income tax expense benefit consolidated statements income elected account tax global intangible lowtaxed income enacted part tax cuts jobs act component tax expense period tax incurred significant accounting policies significant accounting policies described remaining appropriate notes consolidated financial statements revenues disaggregation revenues revenues follows year ended december year ended december year ended december millions us europe international total us europe international total us europe international total product sales hiv atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada revenue share symtuza hiv total hiv veklury hepatitis c virus hcv ledipasvir sofosbuvir sofosbuvirvelpatasvir hcv total hcv hepatitis b virus hbv hepatitis delta virus hdv vemlidy viread hbvhdv total hbvhdv cell therapy tecartus yescarta total cell therapy trodelvy ambisome letairis ranexa zydelig total total product sales royalty contract revenues total revenues represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company janssen includes emtriva tybost amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes hepcludex hepsera includes cayston jyseleca revenues major customers following table summarizes revenues customers individually accounted total revenues year ended december percentage total revenues amerisourcebergen corporation cardinal health inc mckesson corporation revenues recognized performance obligations satisfied prior periods revenues recognized performance obligations satisfied prior years related revenue share janssen described note collaborations arrangements royalties licenses intellectual property million million million years ended december respectively revenues product sales net grosstonet deductions recorded extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated grosstonet deductions subsequently resolved estimates assessed period updated reflect current information changes estimates related sales made prior years resulted million million million increase revenues years ended december respectively primarily related changes estimates accrued government rebates allowances sales returns upon product expiration contract balances contract assets consist unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation totaled million million december respectively contract liabilities generally result receipt advance payment performance contract material december respectively revenue expected recognized future contract liabilities related performance obligations satisfied expected material one year fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist primarily cash cash equivalents marketable debt securities accounts receivable foreign currency exchange contracts equity securities accounts payable shortterm longterm debt cash cash equivalents marketable debt securities certain equity securities foreign currency exchange contracts reported respective fair values consolidated balance sheets equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer shortterm longterm debt reported amortized costs consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values transfers level level level periods presented following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy december december millions level level level total level level level total assets availableforsale debt securities us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities equity securities money market funds equity investment galapagos equity investment arcus publicly traded equity securities deferred compensation plan foreign currency derivative contracts total liabilities liability myr gmbh myr contingent consideration deferred compensation plan foreign currency derivative contracts total see note collaborations arrangements additional information equity securities following table summarizes classification equity securities measured fair value recurring basis consolidated balance sheets millions december december cash cash equivalents prepaid current assets longterm assets total changes fair value equity securities resulted net unrealized losses million billion net unrealized gains billion years ended december respectively included income expense net consolidated statements income equity securities equity method investments equity investments without readily determinable fair values million million december respectively excluded tables amounts included longterm assets consolidated balance sheets related party transaction second quarter donated certain equity securities fair value gilead foundation california nonprofit organization foundation foundation related party certain officers company also serve directors foundation donation expense million recorded within selling general administrative expenses consolidated statements income year ended december level inputs estimate fair values level investments taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates london interbank offered rates libor swap rates inputs applicable observable commonly quoted intervals total estimated fair values aggregate shortterm longterm debt determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs connection first quarter acquisition myr measured assets acquired liabilities assumed fair value nonrecurring basis except liability contingent consideration estimated fair value liability contingent consideration million million acquisition date december respectively change estimated fair value acquisition date primarily due effect foreign exchange remeasurement contingent consideration estimated using probabilityweighted scenarios us food drug administration fda approval hepcludex see note acquisitions additional information connection fourth quarter acquisition immunomedics inc immunomedics measured assets acquired liabilities assumed fair value nonrecurring basis liability assumed related sale future royalties subsequently amortized using effective interest method remaining estimated life fair values liability related sale future royalties billion billion december respectively carrying value billion december see note acquisitions note debt credit facilities additional information connection collaborations equity arrangements entered pionyr immunotherapeutics inc pionyr tizona therapeutics inc tizona also measured fair values exclusive options acquire remaining outstanding capital stock pionyr tizona nonrecurring basis see note collaborations arrangements additional information measured iprd intangible assets acquired connection acquisition kite pharma inc kite fair value nonrecurring basis recognized pretax impairment charge million fair values acquired iprd assets estimated based probabilityadjusted discounted cash flow calculations using level fair value measurements inputs include estimated revenues costs probability technical regulatory success discount rates amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts see note goodwill intangible assets additional information policy recognize transfers level classification actual date event change circumstances caused transfer transfers level level level periods presented availableforsale debt securities following table summarizes availableforsale debt securities december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated millions cost gains losses fair value cost gains losses fair value us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities total following table summarizes classification availableforsale debt securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable debt securities longterm marketable debt securities total following table summarizes availableforsale debt securities contractual maturity december millions amortized cost fair value within one year one year five years five years total held total positions unrealized loss positions december respectively aggregated gross unrealized losses availableforsale debt securities material years ended december impairment recognized years ended december derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturities months less upon executing hedging contract reporting period thereafter assess hedge effectiveness using regression analysis unrealized gains losses aoci reclassified product sales consolidated statements income respective hedged transactions affect earnings majority gains losses related hedged forecasted transactions reported aoci december expected reclassified product sales within months cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts gross basis following table summarizes classification fair values derivative instruments consolidated balance sheets december derivative assets derivative liabilities fair fair millions classification value classification value derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued current liabilities total derivatives designated hedges total derivatives december derivative assets derivative liabilities fair fair millions classification value classification value derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued current liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated financial statements year ended december millions derivatives designated hedges gain loss recognized aoci gain loss reclassified aoci product sales derivatives designated hedges gain loss recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income discontinuances cash flow hedges years presented december held foreign currency exchange contracts following table summarizes potential effect offsetting foreign currency exchange contracts consolidated balance sheets gross amounts offset consolidated balance sheets amounts gross amounts assetsliabilities gross amounts offset presented derivative recognized consolidated balance consolidated balance financial cash collateral net amount millions assetsliabilities sheets sheets instruments receivedpledged legal offset december derivative assets derivative liabilities december derivative assets derivative liabilities acquisitions myr first quarter completed acquisition myr german biotechnology company myr focuses development commercialization therapeutics treatment hdv acquisition provided gilead hepcludex conditionally approved european medicines agency ema july treatment chronic hdv infection adults compensated liver disease upon closing myr became whollyowned subsidiary gilead financial results myr included consolidated financial statements date acquisition acquisitionrelated expenses material year ended december aggregate consideration acquisition billion billion primarily consisted billion billion paid upon closing contingent consideration million subject customary adjustments representing potential future milestone payment upon fda approval hepcludex fair value contingent liability estimated using probabilityweighted scenarios fda approval million acquisition date initially recorded longterm obligations consolidated balance sheets second quarter balance reclassified accrued current liabilities consolidated balance sheets estimated fair value contingent liability million december change estimated fair value acquisition date primarily due effect foreign exchange remeasurement acquisition myr accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed generally recognized fair value acquisition date fair value estimates assets acquired liabilities assumed based upon valuations using information known knowable date filing changes assumptions estimates could cause impact valuation assets acquired including intangible assets goodwill related tax impacts acquisition well legal contingencies amounts recognized finalized information necessary complete analysis obtained later one year acquisition date following table summarizes estimated fair values assets acquired liabilities assumed acquisition date millions amount intangible assets finitelived intangible asset acquired iprd deferred income taxes net assets liabilities net total identifiable net assets goodwill total consideration intangible assets finitelived intangible asset million represents estimated fair value hepcludex hdv europe acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable hepcludex hdv europe discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired iprd consists hepcludex hdv regions without regulatory approval including united states estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable asset discount rate discount rate used represents estimated rate market participants would use value intangible asset significant assumptions inherent development intangible asset fair values include estimates projected future cash flows including revenues operating profits probability success discount rate selected life potential commercialized products risks related viability potential alternative treatments future target markets among factors inputs used valuing identifiable intangibles unobservable considered level fair value measurement disclosure guidance see note fair value measurements additional information deferred income taxes net deferred tax liability based upon difference estimated financial statement basis tax basis net assets acquired estimate final preacquisition net operating losses myr goodwill excess consideration transferred fair values assets acquired liabilities assumed million recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized myr expected deductible income tax purposes material measurement period adjustments recorded fair values assets acquired liabilities assumed year ended december immunomedics fourth quarter completed acquisition immunomedics company focused development antibodydrug conjugate technology cash consideration billion upon closing immunomedics became whollyowned subsidiary gilead acquisition financed majority proceeds september senior unsecured notes offering additional billion borrowing new senior unsecured term loan facility cash hand repaid borrowing senior unsecured term loan facility see note debt credit facilities additional information recorded sharebased compensation expense million related cash settlement accelerated sharebased compensation expense attributable postcombination period primarily recorded selling general administrative expenses research development expenses consolidated statements income year ended december also recorded acquisitionrelated expenses million primarily representing closing costs related fees selling general administrative expenses consolidated statements income year ended december acquisition immunomedics accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed generally recognized fair value acquisition date material measurement period adjustments recorded fair values assets acquired liabilities assumed year ended december fair value estimates assets acquired liabilities assumed completed following table summarizes fair values assets acquired liabilities assumed acquisition date millions amount cash cash equivalents inventories intangible assets finitelived intangible asset acquired iprd outlicense contract deferred tax liabilities liability related future royalties assets liabilities net total identifiable net assets goodwill total consideration transferred inventories fair value stepup adjustment million included inventories million acquisition date primarily determined estimated selling price finished inventory less cost complete manufacturing process selling effort stepup adjustment recorded cost goods sold consolidated statements income inventory sold customers research development expenses consolidated statements income inventory used clinical purposes intangible assets finitelived intangible asset billion represents estimated fair value trodelvy metastatic triplenegative breast cancer tnbc acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable trodelvy metastatic tnbc discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired iprd assets consist trodelvy hormone receptor positive human epidermal growth factor receptor negative metastatic breast cancer trodelvy nonsmall cell lung cancer trodelvy urothelial cancer uc estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable assets discount rate discount rate used represents estimated rate market participants would use value intangible assets trodelvy uc granted accelerated approval fda april billion reclassified finitelived intangibles iprd see note goodwill intangible assets additional information significant assumptions inherent development intangible asset fair values include amount timing projected future cash flows including revenue cost sales research development costs sales marketing expenses probability success discount rate selected measure inherent risk future cash flows assessment assets life cycle competitive trends impacting asset among factors also recorded intangible asset related license supply agreement third party entered immunomedics prior acquisition agreement third party granted exclusive license develop commercialize trodelvy certain territories asia make certain sales milestones royalty payments us acquisition date fair value million determined estimating probabilityweighted net cash flows attributable outlicense discount rate discount rate represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years straightline basis inputs used valuing identifiable intangibles unobservable considered level fair value measurement disclosure guidance deferred income taxes net deferred tax liability based upon difference estimated financial statement basis tax basis net assets acquired estimate final preacquisition net operating losses immunomedics liability related future royalties assumed liability related funding arrangement originally entered immunomedics rpi finance trust rpi prior acquisition immunomedics funding agreement rpi right receive certain royalty amounts subject certain reductions based net sales trodelvy calendar quarter term agreement approximately acquisition date fair value liability estimated billion primarily determined based current estimates future royalty payments rpi life arrangement using real options method effective annual interest rate liability amortized using effective interest rate method resulting recognition interest expense years estimated timing amount future expected royalty payments estimated term reassessed reporting period impact changes estimates recognized liability related interest expense prospectively inputs used valuation liability unobservable considered level fair value measurement disclosure guidance see note fair value measurements additional information liability related future royalties categorized debt primarily included longterm debt net consolidated balance sheets see note debt credit facilities additional information goodwill excess consideration transferred fair values assets acquired liabilities assumed billion recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized immunomedics expected deductible income tax purposes forty seven inc forty seven second quarter completed acquisition forty seven clinicalstage immunooncology company focused developing therapies targeting cancer immune evasion pathways specific cell targeting approaches total consideration billion net acquired cash upon closing forty seven became whollyowned subsidiary gilead accounted transaction asset acquisition since lead asset magrolimab represented substantially fair value gross assets acquired year ended december recorded billion charge representing acquired iprd asset alternative future use acquired inprocess research development expenses stockbased compensation expense million primarily research development expenses consolidated statements income inventories following table summarizes inventories december millions raw materials work process finished goods total reported inventories longterm assets total amounts reported longterm assets primarily consisted raw materials december total inventories december include million million respectively fair value adjustments resulting immunomedics acquisition inventory writedown charges million million million years ended december respectively year ended december million million inventory writedown charges related slowmoving excess raw material work process inventory primarily due lower longterm demand hcv products property plant equipment following table summarizes property plant equipment net december millions land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total unamortized capitalized software costs included office computer equipment million million december respectively capitalized interest construction progress included property plant equipment net consolidated balance sheets interest capitalized material net book value property plant equipment united states billion billion december respectively corresponding amount international locations million million december respectively individual international locations accounted less total balances goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill december millions beginning balance goodwill resulting acquisitions measurement period adjustments ending balance perform annual goodwill impairment assessment fourth quarter earlier impairment indicators exist december accumulated goodwill impairment losses intangible assets following table summarizes intangible assets net december december gross foreign currency gross foreign currency carrying accumulated translation net carrying carrying accumulated translation net carrying millions amount amortization adjustment amount amount amortization adjustment amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel intangible asset trodelvy intangible asset hepcludex total finitelived assets indefinitelived assets iprd total intangible assets gross carrying amount december includes million reclassified first quarter indefinitelived assets iprd following march fda approval yescarta treatment adult patients relapsed refractory follicular lymphoma gross carrying amount december includes trodelvy metastatic tnbc trodelvy use adult patients locally advanced metastatic uc amount related uc billion reclassified finitelived assets indefinitelived assets iprd upon accelerated approval fda april october fda granted approval tecartus treatment adult patients relapsed refractory bcell precursor acute lymphoblastic leukemia accordingly related amount million reclassified finitelived assets fourth quarter gross carrying amount december includes iprd acquisition myr remaining iprd acquisition immunomedics gross carrying amount december includes iprd acquisition immunomedics remaining iprd acquisition kite aggregate amortization expense related finitelived intangible assets billion billion billion years ended december respectively primarily included cost goods sold consolidated statements income amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts performed qualitative assessment iprd intangible asset obtained connection first quarter acquisition myr identify indicators impairment performed quantitative impairment testing iprd intangible assets myr asset described using probabilityweighted income approach discounts expected future cash flows present value using discount rates respectively discount rates based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets also require use level fair value measurements inputs including estimated revenues costs probability technical regulatory success iprd impairment charges recorded lowered estimated revenues related iprd intangible asset axicabtagene ciloleucel treatment indolent bcell nonhodgkin lymphoma due changes estimated market opportunities new therapies combinations existing therapies approved lower estimated revenues reduced fair value iprd intangible assets carrying value resulting recognition impairment charge million recorded within acquired inprocess research development expenses consolidated statements income following table summarizes estimated future amortization expense associated finitelived intangible assets december millions amount thereafter total financial information accounts receivable net following table summarizes accounts receivable net december millions accounts receivable less chargebacks less cash discounts less allowances credit losses accounts receivable net accrued current liabilities following table summarizes components accrued current liabilities december millions compensation employee benefits income taxes payable allowance sales returns accrual settlement related bictegravir litigation accrued liabilities accrued current liabilities see note commitments contingencies additional information collaborations arrangements enter licensing strategic collaborations similar arrangements third parties development commercialization certain products product candidates arrangements may involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities arrangements may include nonrefundable upfront payments expense reimbursements payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements also equity investments third parties focused development commercialization products product candidates merck co inc merck march entered license collaboration agreement merck sharp dohme corp subsidiary merck jointly develop commercialize longacting investigational treatments hiv combine gileads investigational capsid inhibitor lenacapavir mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir collaboration initially focus longacting oral injectable formulations terms agreement gilead merck share global development commercialization costs respectively across oral injectable formulation programs longacting oral products approved gilead would lead commercialization united states merck would lead commercialization european union eu rest world longacting injectable products approved merck would lead commercialization united states gilead would lead commercialization eu rest world terms agreement gilead merck would jointly promote combination products united states certain major markets successful would share global product revenues merck equally product revenues surpass certain predetermined per formulation revenue tiers upon passing billion net product sales oral combination given calendar year share revenue would increase revenues threshold calendar year upon passing billion net product sales injectable combination given calendar year share revenue increase revenues threshold calendar year reimbursements research development costs merck recorded within research development expenses consolidated statements income expenses recognized agreement material year ended december revenues recognized agreement year ended december also option license certain mercks investigational oral integrase inhibitors develop combination lenacapavir reciprocally merck option license certain gileads investigational oral integrase inhibitors develop combination islatravir company may exercise option investigational oral integrase inhibitor company within first five years execution agreement following completion first phase clinical trial integrase inhibitor upon exercise option companies split development costs revenues unless nonexercising company decides optout case nonexercising company paid royalty december merck announced decision parties stop dosing participants phase clinical study evaluating oralweekly combination treatment regimen lenacapavir islatravir following decision fda place clinical holds investigational new drug applications certain formulations islatravir arcus may entered transaction arcus publicly traded oncologyfocused biopharmaceutical company included entry option license collaboration agreement collaboration agreement common stock purchase agreement investor rights agreement together subsequently amended stock purchase agreements accordance terms collaboration agreement stock purchase agreements closed july made upfront payment million acquired approximately million shares arcus common stock approximately million total million initial cash payments including transactional costs made agreements recorded million equity investment calculated based arcus closing stock price closing date transaction remaining million attributed acquired license option rights million representing iprd assets alternative future use ii million issuance premium equity purchase iii million direct transactional costs amounts expensed acquired inprocess research development expenses year ended december consolidated statements income stock purchase agreements right purchase additional shares arcus arcus fiveyear period beginning closing stock purchase agreements maximum outstanding voting stock subject threeyear standstill restricting ability acquire voting stock arcus exceeding thenissued outstanding voting stock arcus subject certain exceptions additionally agreed dispose equity securities arcus prior second anniversary closing stock purchase agreements without prior consent arcus subject certain exceptions may separate secondary equity offering acquired million shares common stock arcus approximately million first quarter also acquired approximately million additional shares arcus common stock million result currently total million shares arcus represented approximately issued outstanding voting stock arcus immediately following closing first quarter transaction pursuant collaboration agreement gilead right opt current future clinicalstage product candidates ten years following closing transaction november exercised options three arcus clinical stage programs amended collaboration agreement option exercise amendment transaction closed december triggering collaboration optin payments million waiving million option continuation payment would due arcus third quarter net option charge million recorded within research development expenses consolidated statements income year ended december collaboration optin payments million recorded accrued current liabilities consolidated balance sheets december paid arcus january payments arcus included within net cash provided investing activities consolidated statements cash flows first quarter amended collaboration agreement companies codevelop share global costs related clinical programs optioned molecules achieve regulatory approval companies cocommercialize equally share profits us gilead hold exclusive commercialization rights outside us subject rights arcuss existing collaboration partners pay arcus tiered royalties percentage net sales ranging midteens low twenties collaboration agreement may also pay additional million option fourth sixth eighth anniversaries agreement unless terminated early maintain rights optin future arcus programs duration contact term elected applied fair value option account equity investment arcus whereby investment marked market reporting period based market price arcus shares believe fair value option best reflects underlying economics investment years ended december recorded pretax unrealized gains million million respectively related investment arcus income expense net consolidated statements income initially recorded equity investments arcus longterm assets consolidated balance sheets investments subject contractual lockup provisions period two years closing date stock purchase agreements subject certain conditions third quarter reclassified equity investments arcus prepaid current assets consolidated balance sheets contractual lockup provisions expected expire july equity investment arcus million million december respectively pionyr june entered transaction pionyr privately held company pursuing novel biology field immunooncology included entry two separate merger agreements one contemplating initial acquisition equity interest pionyr providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock pionyr together pionyr merger option agreements research development service agreement july closed transaction made cash payments million account investment pionyr using equity method accounting equity interest provides us ability exercise significant influence pionyr investment pionyr consisting transaction price noted transaction costs exceeded prorata portion pionyr 's net assets transaction closing determined resulting basis difference primarily relates pionyrs iprd alternative future use pionyr business defined asc business combinations result immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income year ended december carrying value equity method investment pionyr zero december estimated fair value exclusive option acquire remaining outstanding capital stock pionyr approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets may choose exercise exclusive option purchase remaining equity interest pionyrs current shareholders million option exercise fee billion potential future milestone payments upon achievement certain development regulatory milestones option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials pionyr research development service agreement made initial cash funding million recorded charge acquired inprocess research development expenses consolidated statements income year ended december addition committed provide additional payments million pionyr upon achievement certain development milestones accrued million milestone payments related initiation two phase studies charge research development expenses consolidated statements income year ended december payment made first quarter tizona july entered transaction tizona privately held company developing cancer immunotherapies included entry two separate merger agreements one contemplating initial acquisition equity interest tizona providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock tizona together tizona merger option agreements development agreement august closed transaction tizona made cash payments million tizonas shareholders accordance terms tizona merger option agreements account investment tizona using equity method accounting equity interest provides us ability exercise significant influence tizona investment tizona consisting transaction price noted transaction costs exceeded prorata portion tizonas net assets transaction closing determined resulting basis difference primarily relates tizonas iprd alternative future use tizona business defined asc business combinations result year ended december immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income carrying value equity method investment tizona zero december estimated fair value exclusive option acquire remaining outstanding capital stock tizona approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets may choose exercise exclusive option purchase remaining equity interest tizonas current shareholders million option exercise fee billion potential future milestone payments upon achievement certain development regulatory milestones option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials tizona development agreement committed provide funding tizona million recorded acquired inprocess research development expenses consolidated statements income year ended december tango therapeutics inc tango august entered transaction tango privately held company pursuing innovative targeted immune evasion therapies patients cancer proprietary crisprenabled functional genomics target discovery platform included entry amended restated research collaboration license agreement stock purchase agreement together tango collaboration stock purchase agreements upon entering transaction made upfront payment million million equity investment tango year ended december recorded million upfront expense acquired inprocess research development expenses consolidated statements income third quarter made additional million equity investment tango became publicly traded company third quarter accordingly equity investment recorded prepaid current assets consolidated balance sheets fair market value december tango collaboration stock purchase agreements gilead right option programs sevenyear collaboration million per program optin extension milestone payments products tango opts codevelop copromote parties equally split profits losses well development costs us products tango opt codevelop copromote pay tango low doubledigit tiered royalties net sales provide tango milestone payments royalties sales outside us jounce therapeutics inc jounce september entered transaction jounce publicly traded company developing novel cancer immunotherapies included entry license registration rights stock purchase agreements together jounce license stock purchase agreement october closed transaction made total payment million recorded million upfront expense acquired inprocess research development expenses consolidated statements income million equity investment longterm assets consolidated balance sheets representing approximately issued outstanding voting stock jounce immediately following transaction calculated based jounces closing stock price closing date transaction december jounce eligible receive us million future potential clinical regulatory commercial milestone payments upon achievement certain milestones royalties ranging high single digit midteens based upon worldwide sales subject certain adjustments galapagos filgotinib collaboration closed license collaboration agreement galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications filgotinib agreement upon closing made upfront license fee payment equity investment galapagos subscribing million new ordinary shares galapagos price per share amended terms agreement terms filgotinib agreement amended agreement obtained exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib december following type meeting fda discuss points raised complete response letter related new drug application filgotinib treatment rheumatoid arthritis gilead galapagos agreed amend agreement allow galapagos assume development manufacturing commercialization certain rights filgotinib europe parties reflected amendment agreement december beginning january galapagos bore development costs certain studies lieu equal cost split contemplated agreement parties transferred filgotinibs marketing authorizations eu great britain galapagos december january commercial economics filgotinib europe transferred galapagos subject payment tiered royalties net sales europe gilead starting connection amendments agreement gilead agreed irrevocably pay galapagos million approximately million subject certain adjustments higherthanbudgeted development costs total amount gilead paid million approximately million january paid additional million approximately million april pay million approximately million accrued full amount liability charge research development expenses consolidated statements income year ended december addition galapagos longer eligible receive future milestone payments relating filgotinib europe global collaboration august closed option license collaboration agreement galapagos collaboration agreement subscription agreement galapagos subscription agreement galapagos pursuant parties entered global collaboration covers galapagos current future product portfolio filgotinib upon closing paid billion license option rights million new ordinary shares galapagos subscription price per share fair value billion included issuance discount million calculated based galapagos closing stock price date closing galapagos subscription agreement remaining billion payment recorded within acquired inprocess research development expenses consolidated statements income year ended december pursuant galapagos subscription agreement issued warrants confer right subscribe time time number new shares issued galapagos sufficient bring number shares owned us issued outstanding shares time exercises exercised warrant subscribe million ordinary shares galapagos per share purchased shares open market aggregate fair value million brought number shares owned us million approximately shares issued outstanding subject year standstill restricting ability acquire voting securities galapagos exceeding thenissued outstanding voting securities galapagos agreed without prior consent galapagos dispose equity securities galapagos prior second anniversary closing galapagos subscription agreement dispose equity securities galapagos thereafter fifth anniversary closing galapagos subscription agreement disposal would less thenissued outstanding voting securities galapagos subject certain exceptions termination events april amended galapagos subscription agreement extend initial lockup provision certain galapagos shares august august two designees appointed galapagos board directors initial contractual lockup provision certain galapagos shares due expire august million included within prepaid current assets consolidated balance sheets remainder billion included within longterm assets consolidated balance sheets december subsequent extension contractual lockup period equity investment galapagos classified long term assets consolidated balance sheets million december elected fair value option account equity investment galapagos whereby investment marked market earnings reporting period based market price galapagos shares believe fair value option best reflects underlying economics investment years ended december recorded pretax unrealized losses million billion pretax unrealized gain billion respectively related investment galapagos income expense net consolidated statements income due changes galapagos stock price galapagos collaboration agreement exclusive license development commercialization glpg latestage candidate idiopathic pulmonary fibrosis territories option participate development commercialization galapagos current future clinical programs entered clinical development first ten years collaboration subject extension certain circumstances gilead galapagos terminated phase clinical studies glpg february respect programs galapagos current future pipeline exercise option program pay million option exercise fee per program addition galapagos receive tiered royalties ranging net sales territories galapagos product optioned us exercise option program parties share equally development costs mutually agreed commercialization costs incurred subsequent exercise option may terminate collaboration entirety programbyprogram countrybycountry basis advance notice well following customary termination events janssen compleraeviplera odefsey entered license collaboration agreement janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved us eu sold brand name complera us eviplera eu agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside us neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues including major markets sales products included product sales janssens share revenues included cost goods sold consolidated statements income cost goods sold relating janssens share million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide gilead compounds combination approved us eu july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco inc japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales sales products included product sales consolidated statements income royalties due japan tobacco included cost goods sold consolidated statements income royalty expenses recognized million million million years ended december respectively terms agreement paid japan tobacco million cash recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause gadeta bv gadeta july entered collaboration arrangement gadeta made purchase equity gadeta gadetas shareholders determined gadeta vie primary beneficiary power direct activities gadeta significantly impact economic performance upon initial consolidation gadeta recorded million noncontrolling interest primarily reflecting acquired intangible assets related iprd consolidated balance sheets year ended december effectively terminated agreement gadeta upon effective termination ceased controlling interest deconsolidated vie removing related net assets noncontrolling interest million consolidated balance sheets net loss deconsolidation material collaboration arrangements individually significant entered several collaborations equity investments licensing arrangements well similar arrangements consider individually material recorded upfront collaboration expenses related arrangements million million million years ended december respectively within acquired inprocess research development expenses consolidated statements income cash payments equity investments noted years ended december million million million respectively primarily recorded within prepaid current assets longterm assets consolidated balance sheets financial terms arrangements may required make payments upon achievement various developmental regulatory commercial milestones could significant future milestone payments reflected consolidated statements income corresponding events become probable connection regulatory approvals milestone payments made capitalized intangible assets amortized cost goods sold terms collaboration arrangements addition may required pay significant royalties future sales products related arrangements commercialized payment amounts however contingent upon occurrence various future events high degree uncertainty debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions december type borrowing issue date due date interest rate senior unsecured march april senior unsecured september september month libor senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured september september month libor senior unsecured september september term loan october october variable senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october total senior unsecured notes term loan facility liability related future royalties total debt net less current portion longterm debt obligations net total longterm debt net senior unsecured notes term loan facility repaid billion debt consisting billion senior unsecured notes billion senior unsecured term loan facility repaid billion senior unsecured notes due april first quarter billion senior unsecured notes due december third quarter additionally repaid million senior unsecured floating rate notes due upon maturity september october exercised option call million senior unsecured floating rate notes million senior unsecured notes final maturity date september two early repayments totaling billion principal amount made fourth quarter december exercised option call million senior unsecured notes final maturity march notes repaid february new debt issued senior unsecured fixed rate notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined indenture senior unsecured fixed rate notes also call feature exercisable option redeem notes par whole part dates ranging one month two years prior maturity case accrued unpaid interest also required redeemed date redemption billion senior unsecured notes due september also call feature exercisable option redeem notes par whole part september event occurrence change control downgrade rating senior unsecured notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants note indentures governing senior unsecured notes december violation covenants september entered commitment letter group institutional lenders provide threeyear senior unsecured term loan facility aggregate principal amount billion october connection acquisition immunomedics entered term loan credit agreement term loan facility borrowed aggregate principal amount billion repaid billion principal amount outstanding term loan facility due upon maturity october liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi prior acquisition immunomedics liability related future royalties primarily included longterm debt net consolidated balance sheets see note acquisitions additional information revolving credit facilities june terminated billion fiveyear revolving credit facility maturing may revolving credit facility entered new billion fiveyear revolving credit facility maturing june revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facility revolving credit facility contains customary representations warranties affirmative negative covenants events default december compliance covenants loans revolving credit facility bear interest either eurodollar rate plus applicable percentage ii base rate plus applicable percentage defined revolving credit facility agreement may terminate reduce commitments may prepay loans credit facility whole part time without premium penalty contractual maturities financing obligations following table summarizes aggregate future principal maturities senior unsecured notes december millions amount thereafter total interest expense interest expense debt credit facilities related contractual coupon rates amortization debt discount issuance costs billion leases operating leases consist primarily properties equipment administrative manufacturing rd activities leases include options extend terms years include options terminate lease within one year lease commencement date december material finance leases operating lease expense including variable costs shortterm leases million million million respectively following table summarizes balance sheet information related operating leases december millions except weighted average amounts classification rightofuse assets net longterm assets lease liabilities current accrued current liabilities lease liabilities noncurrent longterm obligations weighted average remaining lease term years years weighted average discount rate following table summarizes supplemental information related operating leases year ended december millions cash paid amounts included measurement lease liabilities rightofuse assets obtained exchange lease liabilities following table summarizes maturity analysis operating lease liabilities showing aggregate lease payments december millions amount thereafter total undiscounted lease payments less imputed interest total discounted lease payments commitments contingencies legal proceedings party various legal actions significant described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted outcome matters either expected material possible determine reasonably estimate maximum potential exposure range possible loss third quarter reversed million previously recorded litigation accrual following favorable court decision litigation related axicabtagene ciloleucel described fourth quarter recorded accrual billion accrued current liabilities consolidated balance sheets settlement related bictegravir litigation described litigation related sofosbuvir acquired pharmasset inc acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv received approval fda sofosbuvir known commercially sovaldi sofosbuvir also included marketed hcv products received number litigation claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims litigation university minnesota university minnesota university obtained us patent patent purports broadly cover nucleosides antiviral anticancer activity university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir court granted motion transfer case california also filed petitions inter partes review us patent trademark office patent trial appeal board ptab alleging asserted claims invalid anticipation obviousness ptab instituted one petitions merits hearing held february us district court northern district california stayed litigation ptab concludes inter partes review initiated may ptab issued written decision finding asserted claims universitys patent invalid july university appealed decision litigation us district court remain stayed appeal proceedings litigation nucana plc nucana nucana obtained european patent ep patent allegedly covers sofosbuvir opposition proceedings european patent office epo held february epo opposition division upheld validity ep patent amended form believe amended ep patent claims invalid subsequently initiated proceedings invalidate uk counterpart ep patent high court england wales march nucana filed counterclaim us high court england wales alleging patent infringement uk counterpart seeking damages relief april nucana also filed lawsuit us germany landgericht dsseldorf alleging patent infringement german counterpart ep patent seeking damages injunctive relief hearing date german nucana case scheduled may hearing date uk nucana case scheduled january litigation related axicabtagene ciloleucel october juno therapeutics inc sloan kettering cancer center collectively juno filed lawsuit us us district court central district california alleging commercialization axicabtagene ciloleucel sold commercially yescarta infringes us patent patent jury trial held patent december jury found asserted claims patent valid willfully infringed asserted claims patent jury also awarded juno damages amounts million upfront payment running royalty october date jurys verdict parties filed posttrial motions first quarter trial judge entered judgment april trial judge affirmed jurys verdict enhanced past damages maintained royalties future yescarta sales april filed appeal seeking reverse judgment obtain new trial due errors made trial judge july appeals court heard oral arguments august court appeals federal circuit cafc reversed jury verdict finding asserted claims junos patent invalid october juno filed petition rehearing cafc january cafc denied junos petition rehearing believe likelihood material adverse outcome matter remote litigation related bictegravir viiv healthcare company vhc filed lawsuit us us district court delaware alleging commercialization bictegravir sold commercially combination tenofovir alafenamide emtricitabine biktarvy infringes vhcs us patent patent covering vhcs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent lawsuit vhc seeking billions dollars alleged damages comprised vhcs lost profits royalty us sales bictegravir launch trial addition court find liable infringement also expected vhc seek royalty us sales trial vhc also filed lawsuit us federal court canada alleging activities relating bictegravir compound infringes vhcs canadian patent patent issued shionogi co ltd vhc patent compound patent covering vhcs dolutegravir believe bictegravir infringe claims patent november december vhc filed lawsuits france germany ireland uk asserting relevant national designations european patent australia asserting australian patent japan asserting japanese patent korea asserting korean patent nos patents relate molecules vhc claims would act integrase inhibitors believe bictegravir infringe valid claims vhcs patents prevailed court proceedings date canada germany february gilead reached agreement settlement vhc viiv healthcare uk limited viiv healthcare uk limited shionogi co ltd glaxosmithkline mercury limited collectively viiv global resolution pending potential claims related gileads sales biktarvy including litigation pending us district court delaware jurisdictions outside united states described february lawsuit pending united states dismissed well lawsuits canada france ireland uk australia japan korea pursuant terms settlement viiv grants gilead broad worldwide license covenant sue relating past present future development commercialization bictegravir connection settlement gilead made onetime payment viiv billion first quarter provide viiv ongoing royalty rate future sales biktarvy bictegravir component bictegravircontaining products united states october connection settlement gilead recorded pretax charge billion cost goods sold consolidated statements income fourth quarter litigation relating preexposure prophylaxis august filed petitions requesting inter partes review us patent nos collectively hhs patents ptab hhs patents assigned us department health human services hhs purport claim process protecting primate host infection immunodeficiency retrovirus administering combination emtricitabine tenofovir disoproxil fumarate tdf prior exposure host immunodeficiency retrovirus process commonly known preexposure prophylaxis prep november us department justice filed lawsuit us us district court delaware alleging sale truvada descovy use prep infringes hhs patents february ptab declined institute petitions inter partes review hhs patents april filed breach contract lawsuit us federal government us court federal claims alleging violations four material transfer agreements mtas related research underlying hhs patents clinical trial agreement cta us centers disease control prevention related prep research although predict certainty ultimate outcome litigation matters believe us federal government breached mtas cta truvada descovy infringe hhs patents hhs patents invalid prior art descriptions truvadas use prep postexposure prophylaxis well physicians patients using claimed methods years hhs filed applications patents trial date lawsuit court federal claims set june trial date lawsuit district court delaware set may litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products prior patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval starting december received letters lupin ltd apotex inc shilpa medicare ltd shilpa sunshine lake pharma co ltd sunshine lake laurus labs natco pharma ltd macleods pharma ltd hetero labs ltd cipla ltd collectively generic manufacturers indicating submitted andas fda requesting permission market manufacture generic versions certain tafcontaining products generic manufacturers seek market generic versions odefsey descovy vemlidy generic manufacturers challenged validity two four patents listed orange book associated taf filed lawsuits generic manufacturers intend enforce defend intellectual property november reached agreement shilpa resolve lawsuit shilpa addition january reached agreement sunshine lake resolve lawsuit sunshine lake settlement agreements filed us federal trade commission us department justice required law october received letter lupin ltd lupin indicating submitted anda fda requesting permission market manufacture generic version symtuza product commercialized janssen gilead shares revenues november along janssen products lp janssen filed patent infringement lawsuit lupin coplaintiffs us district court delaware separately filed additional lawsuit lupin asserting infringement two additional patents court european patent claims several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal hearing originally scheduled july canceled new date yet set epo several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires epo conducted oral hearing opposition upheld claims two original opposing parties appealed requesting full revocation several parties filed oppositions epo requesting revocation granted european patent covering taf expires epo upheld validity claims taf patent three parties appealed decision appeal hearing held march validity claims upheld several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires epo upheld validity claims taf hemifumarate patent three parties appealed decision three parties filed oppositions epo requesting revocation granted european patent covering cobicistat expires epo upheld validity claims cobicistat patent two parties appealed decision appeal process may take several years epo opposition proceedings confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf taf hemifumarate cobicistat eu could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted ema lose patent protection compounds revenues results operations could negatively impacted years including succeeding year exclusivity lost antitrust consumer protection along bristolmyers squibb company bms johnson johnson inc named defendants class action lawsuits filed related various drugs used treat hiv including drugs used combination antiretroviral therapy plaintiffs allege defendants engaged various conduct restrain competition violation federal state antitrust laws state consumer protection laws lawsuits consolidated pending us district court northern district california lawsuits seek bring claims behalf two nationwide classesone direct purchasers consisting largely wholesalers another indirect endpayor purchasers including health insurers individual patients plaintiffs seek damages permanent injunctive relief relief fall several plaintiffs filed separate lawsuits effectively opting class action cases asserting claims substantively putative classes cases coordinated class actions trial set march september along generic manufacturers cipla ltd cipla usa inc together cipla named defendants class action lawsuit filed us district court northern district california jacksonville police officers fire fighters health insurance trust jacksonville trust behalf endpayor purchasers jacksonville trust claims settlement agreement us cipla settled patent dispute relating patents covering emtriva truvada atripla products permitted generic entry prior patent expiry violates certain federal state antitrust consumer protection laws plaintiff seeks damages permanent injunctive relief relief february along bms teva pharmaceutical industries ltd named defendants lawsuit filed first judicial district court state new mexico county santa fe new mexico attorney general new mexico attorney general alleges defendants restrained competition violation new mexico antitrust consumer protection laws new mexico attorney general seeks damages relief believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages could subject permanent injunctive relief awarded favor plaintiffs product liability named defendant one class action lawsuit various product liability lawsuits related viread truvada atripla complera stribild plaintiffs allege viread truvada atripla complera andor stribild caused experience kidney bone andor tooth injuries lawsuits pending state federal court california delaware maryland missouri new jersey involve plaintiffs plaintiffs cases seek damages relief various grounds alleged personal injury economic loss intend vigorously defend actions believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages government investigation received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry qui tam litigation former sales employee filed qui tam lawsuit gilead march us district court eastern district pennsylvania following governments decision intervene suit case unsealed december lawsuit alleges certain gileads hcv sales marketing activities violated federal false claims act various state false claims acts relator seeks available relief statutes two former employees filed qui tam lawsuit gilead april california state court following california attorney generals offices decision intervene relators served gilead complaint august complaint alleges violations california false claims act cfca employment law claims relators seek available relief cfca december gilead relators executed settlement agreement resolve lawsuit february court issued order dismissing lawsuit prejudice settlement material impact consolidated financial statements health choice advocates llc health choice filed qui tam lawsuit gilead april new jersey state court following new jersey attorney generals offices decision intervene suit health choice served us original complaint august lawsuit alleges gilead violated new jersey false claims act clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief new jersey false claims act april trial court granted motion dismiss prejudice health choice appealed trial courts dismissal health choice filed another qui tam lawsuit gilead may making similar allegations texas state court following texas attorney generals offices decision intervene suit health choice served us original complaint october lawsuit alleges gilead violated texas medicare fraud prevention act tmfpa clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief tmfpa september texas court appeals sixth court appeals district granted request stay texas litigation case stayed pending final judgment eastern district pennsylvania lawsuit filed march discussed intend vigorously defend actions believe cases without merit predict ultimate outcomes plaintiffs successful claims could required pay significant monetary damages securities litigation immunomedics several former officers directors named defendants putative class actions filed consolidated september plaintiffs filed consolidated complaint november amended complaint july plaintiffs allege immunomedics individual defendants violated federal securities laws connection immunomedics biologics license application trodelvy seek certification class shareholders damages relief consolidated lawsuit pending us district court district new jersey believe case without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter firm purchase commitments related inventory december commitments next five years approximately billion million million million million stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions december remaining authorized repurchase amount programs billion following table summarizes stock repurchases program year ended december millions except per share amounts shares repurchased retired amount average price per share addition repurchases program program repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations shares excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated additional paidin capital based estimated average sales price per issued share excess amounts charged retained earnings dividends following table summarizes cash dividends declared common stock millions except per share amounts dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total restricted stock performance share awards units dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income following table summarizes changes aoci component net tax unrealized gains unrealized gains foreign currency losses available losses cash translation net forsale debt flow hedges net millions tax securities net tax tax total balance december net unrealized gain reclassifications net income net current period comprehensive income loss balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december amounts reclassified net income gains losses cash flow hedges recorded part product sales consolidated statements income see note derivative financial instruments additional information amounts reclassified net income gains losses availableforsale debt securities recorded part income expense net consolidated statements income income tax impact allocated component comprehensive income material periods presented employee benefits equity incentive plans may stockholders approved adopted gilead sciences inc equity incentive plan amended plan plan authorized issuance total million shares common stock part forty seven acquisition assumed forty seven inc equity incentive plan subsequently amended restated gilead sciences inc equity incentive plan amended restated plan aggregate amount shares may issued plan assumption date exceed million shares part immunomedics acquisition assumed immunomedics amended restated longterm incentive plan immunomedics plan referred together plan plan plans subsequently merged plan aggregate amount shares may issued immunomedics plan assumption date exceed million shares see note acquisitions additional information settlement stock awards plans broad based incentive plans provide grant equitybased awards including stock options restricted stock units restricted stock awards performance share awards employees directors consultants december total million shares remain available future grant plans stock options plans provide option grants designated either nonqualified incentive stock options stock options granted january nonqualified stock options employee stock options generally vest three four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value millions dollars years millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million million respectively weightedaverage grant date fair value stock options granted per share per share per share respectively december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years restricted stock performance share awards grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus sharebased awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant fair value rsu equal closing price common stock grant date grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one two year period fair value award equal closing price common stock grant date following table summarizes rsu psu activity related information rsus psus weighted weighted average average grant date fair grant date fair millions except per share amounts shares value per share shares value per share outstanding december granted vested forfeited outstanding december weightedaverage grantdate fair value per share excludes shares related grants currently grant date performance objectives yet defined weightedaverage grant date fair value rsus granted per share per share per share respectively weightedaverage grant date fair value psus granted per share per share per share respectively total grant date fair value vested rsus psus million million million respectively total fair value respective vesting dates million million million respectively december million unrecognized compensation cost related unvested rsus psus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan international employee stock purchase plan together amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers sixmonth lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares million shares issued espp million total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation following table summarizes total stockbased compensation expenses included consolidated statements income year ended december millions cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax pretax stockbased compensation expense year ended december billion included million noncash stockbased expense million million accelerated postacquisition stockbased expense related acquisitions immunomedics forty seven respectively see note acquisitions additional information income tax effect year ended december included million income tax expense following us court appeals decision altera corp v commissioner requires related parties intercompany cost sharing arrangement share expenses related stockbased compensation stockbased compensation recognized expense requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience requisite service period could shorter vesting period employee retirement eligible valuation assumptions fair value options granted plans purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million respectively maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million million december respectively net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents determined treasury stock method potential shares common stock excluded computation diluted net income per share attributable gilead common shareholders effect would antidilutive million million million respectively following table shows calculation basic diluted net income per share attributable gilead common stockholders year ended december millions except per share amounts net income attributable gilead shares used per share calculation basic dilutive effect stock options equivalents shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted income taxes income income taxes consists following year ended december millions domestic foreign income income taxes income tax expense benefit consists following year ended december millions federal current deferred state current deferred foreign current deferred income tax expense benefit income tax benefit included billion deferred tax benefit related intangible asset transfers foreign subsidiary ireland united states fourth quarter completed intraentity asset transfer certain intangible assets foreign subsidiary ireland transaction resulted stepup irish taxdeductible basis transferred assets accordingly created temporary difference tax basis exceeded financial statement basis intangible assets result recognized deferred tax asset billion consolidated financial statements expect able realize deferred tax asset resulting intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material reconciliation federal statutory tax rate applied income income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings foreignderived intangible income deduction deferred tax intraentity transfer intangible assets settlement tax examinations acquired iprd related charges changes valuation allowance nontaxable unrealized gain loss investment effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows december millions deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible excess tax basis book basis intangible assets upfront milestone payments research credit carryforwards equity investments liability related future royalties net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities property plant equipment excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax assets liabilities valuation allowance million million december respectively increase valuation allowance primarily related california research development tax credits valuation allowance million million december respectively increase valuation allowance primarily related acquired attributes related forty seven immunomedics acquisitions capital losses related equity method investments december us federal net operating loss tax credit carryforwards approximately million million respectively start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss state tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns united states many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service irish tax authorities tax years differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits million billion december respectively recognized would reduce effective tax rate period recognition interest penalties related unrecognized tax benefits included income tax expense million income tax benefit million income tax expense million consolidated statements income years ended december respectively accrued interest penalties related unrecognized tax benefits million million december respectively december believe reasonably possible unrecognized tax benefits decrease approximately million next months due potential settlements various taxing authorities following rollforward total gross unrecognized tax benefits year ended december millions balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period connection tax cuts jobs act recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period december accrued billion billion respectively transition tax amounts accrued december approximately million expected paid within one year item changes disagreements accountants accounting financial disclosure applicable report independent registered public accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san jose california february item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae de securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af df exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable item c disclosure regarding foreign jurisdictions prevent inspections applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers applicable delinquent section reports written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website wwwgileadcom investors section corporate governance intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation talent committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading equity compensation plan information section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item